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CHAPTER  1 
AN  OVERVIEW  OF  THE  STUDY 
 
 
1.1 Introduction  
 
The first reference to the practice of gynaecology as a field of medicine is 
found in the Kahun papyrus from 2000 B.C. In a description of women`s 
diseases, Hippocrates, who is considered to be the father of both 
medicine and oncology, referred to cancer of the uterus as a disease with 
a poor prognosis. He recommended the following treatments for  cancer: 
“Regular evacuation of the bowels; the patient is to be given a bath each 
day with lukewarm water; narcotics such as opium given internally or 
injected into the uterus for pain relief; the application of leeches or red-hot 
irons or other caustic agents to the cervix” (Werner 1990). Since the 
discovery of X-rays by Wilhelm Conrad Roentgen in 1895, the treatment of 
uterine cervical cancer by means of radiotherapy has developed 
immensely. 
 
Radiotherapy is a clinical modality that uses ionising radiation in the 
treatment of patients with malignant neoplasias. The aim of radiotherapy is 
to deliver a precisely measured dose of radiation to a defined tumour 
volume with as little damage as possible to surrounding healthy tissue, 
resulting in eradication of the tumour, a high quality of life and 
prolongation of survival at a competitive cost (Halperin, Schmidt-Ulrich, 
Perez & Brady 2004: 3). The current study will look at radiotherapy as 
treatment modality for patients diagnosed with uterine cervical cancer. 
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Uterine cervical cancer occurs in women around the world, irrespective of 
their age and race. The South African cervical cancer screening program 
implemented since 2001 are an attempt to facilitate early detection of  
cervical cancer through the Papanicolaou (PAP) smear (Mqoqi, Kellet, 
Sitas & Jula 2004: 22). Through the screening policy it has become 
evident that cervical cancer is the leading cancer among South African 
women. It is thus crucial to treat patients who have been diagnosed with 
uterine cervical cancer with the best modality currently available. 
 
This current study will look at radiotherapy as the treatment modality 
administered to patients at the Department of Oncotherapy, Bloemfontein, 
diagnosed with uterine cervical cancer, since a new modality of high dose-
rate (HDR)-intracavitary brachytherapy (ICBT) was implemented in 1994. 
Treatment results are quantified and analysed in terms of tumour control 
and late rectal complications. This chapter provides an overview of the 
incidence of uterine cervical cancer, the development of treatment 
protocols at the Department of Oncotherapy, Bloemfontein, and the dose 
effectiveness of HDR-ICBT as an introduction to the problem statement 
and objectives for this study. 
 
 
1.2      Worldwide incidence of cervical cancer 
Worldwide, uterine cervical cancer is one of the most frequently occurring 
cancers in women, with more than 80% occurring in developing countries 
(Stewart & Kleihues 2003: 215). Carcinoma of the uterine cervix is the 
sixth most common malignant neoplasm amongst women in the world, 
after carcinoma of the breast, lung, colorectum, endometrium and ovary 
(Perez & Kavanagh 2004: 1800). From a worldwide perspective, uterine 
cervical cancer remains one of the biggest causes of cancer death in 
women. Globocan 2000 estimated that in the year 2000, the number of 
patients diagnosed with this disease was 470 606, of whom 233 372 died 
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as a result (Parkin, Bray, Ferlay & Pisani 2001: 153). The American 
Cancer Society estimated that in 2001 there were 12 900 new cases of 
invasive uterine cervical cancer in the United States and 4 400 deaths 
from the disease, in addition to over 50 000 cases of carcinoma in situ 
(Perez & Kavanagh 2004: 1800).  
 
The epidemiology of uterine cervical cancer is strongly related to the 
standard of living of populations from the different world regions (Parkin et 
al. 2001: 153). It follows then that for developed countries, in addition to a 
lower incidence of the disease, most cases of uterine cervical cancer are 
detected at a pre-invasive stage where the rates of cure approach 100% 
with local therapies. On the other hand, developing countries present a 
different picture, with most cases being diagnosed with locally advanced 
disease. This requires a much more aggressive treatment approach and, 
in general, the survival prospects are not very encouraging (Duenas-
Gonzalez, Cetina, Mariscal & De la Garza 2003: 390). Nag et al. (2002) 
reported that cervical cancer is the commonest type of cancer in many 
developing countries (Nag, Dally, de la Torre, Tatsuzaki, Kizilash, 
Kurusun, Pinillos, Pokrajac, Sur & Levin 2002: 298). Developing countries 
with a high incidence of cervical cancer are Zimbabwe, Uganda, South 
Africa, Gambia and Algeria. Black Zimbabwean women have the highest 
incidence rates of 55 per 100 000 (Mqoqi et al. 2004: 22). 
 
 
1.3 Cervical cancer in South Africa 
In South Africa, a total of 6 061 and 4 944 uterine cervical cancer cases 
were reported to the National Cancer Registry (NCR) in 1998 and 1999 
respectively. The NCR (established in 1986) is the main cancer data 
source, which publishes pathology-based cancer incidence data in South 
Africa. These are the most recent statistics available and comprise 20% 
and 17% respectively of all cancer cases reported in females over two 
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years. Consequently, uterine cervical cancer was the leading cancer in 
women in 1998 and the second leading cancer in 1999 (Mqoqi et al. 2004: 
22). The incidence of uterine cervical cancer also differs among the 
different population groups in South Africa. Statistics indicate that in 1999 
a total of 4 944 cases were observed, of whom 4 127 were black, 390 
coloured, 371 white and 56 Asian. The statistics for 2000 – 2004 at the 
Department of Oncotherapy, Bloemfontein, has indicated that Black South 
African women were the most affected by this disease (Doman 2006).  
 
1.4 Cervical cancer at the Department of Oncotherapy, Universitas       
Annex, Bloemfontein  
The incidence rate of cervical cancer at the Department of Oncotherapy, 
Universitas Annex, Bloemfontein (Free State, South Africa) is high 
according to the statistics (Doman 2006). The statistics from 2000 to 2004 
in Table 1.1 indicate that a total of 6 285 female patients received 
treatment for cancer over a five year period from January 2000 to 
December 2004. Of these, 2 117 patients (33.7%) were diagnosed  with 
cervical cancer (FIGO stages I-IV) and were treated accordingly.  
 
Table 1.1 Female patients treated for cancer at the Department of 
Oncotherapy, Bloemfontein (Doman:2006) 
  
White 
% of 
whites 
% of 
females Black 
% of 
blacks 
% of 
females Total 
% of 
Total 
% of 
females 
2004 cervix 29 4.25 8.92 389 24.13 43.37 418 18.21 34.21 
 Females 325   897   1222    
2003 cervix 26 4.70 7.78 402 23.52 46.26 428 18.92 35.58 
 Females 334   869   1203    
2002 cervix 36 5.57 11.39 351 22.43 37.70 387 17.50 31.03 
 Females 316   931   1247    
2001 cervix 38 9.69 10.83 412 27.23 42.13 450 20.41 33.86 
 Females 351   978   1329    
2000 cervix 43 6.44 12.50 391 24.15 41.60 434 18.89 33.80 
 Females 344   940   1284   
            
Total  
cervix 172    1945   2117   
 Females 1670    4615   6285   
Average 
 34 6.13 10.29 389 24.29 42.21 423 18.79 33.70 
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Treatment modalities for uterine cervical cancer differ according to the 
disease. Surgery, chemotherapy and radiotherapy, or a combination 
thereof, are currently being used to treat patients diagnosed with uterine 
cervical cancer. Radiotherapy plays an important role in the treatment of 
uterine cervical cancer. A combination of megavoltage external beam 
radiotherapy (EBRT) and intracavitary brachytherapy (ICBT) is the 
accepted definitive mode of treatment of International Federation of 
Gynecologists and Obstetricians (FIGO) stages I-III cervical cancer. The 
curative potential of radiotherapy in the management of carcinoma of the 
cervix is enhanced by the use of intracavitary brachytherapy, which 
delivers a high radiation dose directly to the tumour while sparing  the 
surrounding normal tissues (Patel, Rai, Mallick & Sharma 2005: 125). The 
choice of radiation modality depends on the efficacy, disease site, 
equipment availability, treatment duration, expertise and radiation safety 
considerations (Nag et al. 2002: 298).   
 
How often HDR brachytherapy is used depends on how common a 
particular cancer is in that country and whether that site can be effectively 
treated by HDR brachytherapy. Currently, more than 1 000 units exist in 
the world, including almost 400 in developing countries. The use of HDR-
ICBT for uterine cervical cancer patients is the most common indication for 
brachytherapy, and gynaecological brachytherapy can account for up to 
100% of the brachytherapy practice in some developing countries (Nag et 
al. 2002: 298-299). 
 
The statistics shown in Table 1.1 therefore clearly indicate the need to 
introduce HDR-ICBT into the treatment schedule for FIGO stages I-III 
cervical cancer patients with curative intent. In April 1994 the standard 
prescribed protocol for FIGO stages I-III cervical cancer patients at the 
Department of Oncotherapy, Bloemfontein, South Africa, changed with the 
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installation of a high dose-rate (HDR) Ir192 brachytherapy afterloading unit, 
described in the next section.  
 
 
1.5 Development of treatment protocols at the Department of 
Oncotherapy, Bloemfontein 
Radiotherapy treatment was started in Bloemfontein during 1960 by a 
diagnostic radiologist, Dr R Tahan. A kilovoltage apparatus for teletherapy 
(RT 250, Philips) and radium sources (Radium-226) for brachytherapy 
were the main treatment units during those years. The duration of the 
brachytherapy (Radium-226) was 72 hours and the patient received three 
fractions (Friedrich 1996: 16). The treatment protocols from 1966 to 1990 
for stages IIb and III cervical carcinoma are summarised in Tables 1.2 & 
1.3 respectively (Friedrich 1996: 17). 
 
 
Table 1.2 Treatment protocols at Universitas Annex, stage II  
                           cervical  carcinoma: 1986-1990 (Friedrich 1996). 
YEAR TEATMENT 
PROTOCOLS 
DOSE (Gy) TOTAL DOSE 
(Gy) 
1966 Opposing fields 
 
Planned fields 
Brachytherapy LDR 
(one application 24 
hours) or  
Surgery 
Opposing fields 
followed by Planned 
fields 
2 
2.5 
2 
 
 
 
2 
2 
14 
10 
30 
 
 
 
10 
30 
1967 Opposing fields 
 
 
Brachytherapy (2 
applications 50/54 
hours each) 
Supplementary fields to 
pelvic wall 
2, 2.5 or 
3 
 
 
 
variation 
 
12 
10 
12-15 
 
 
depended on 
brachytherapy 
dose 
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1969  Fractionation 3 x per 
week 
  
1970 Double dose 3.5 to 7 45 - 54 
1972 to 
1990 
Opposing fields 
Brachytherapy (2 x 50 
h) 
Surgery or 
supplementary fields or 
Opposing fields, 
treatment plan and 
brachytherapy LDR 
booster 
3 
 
 
 
 
 
3 
12 -15 
 
 
 
 
 
54 - 60 
 
 
Table 1.3 Treatment protocol stage III cervical carcimoma: 1996-1990 
YEAR TREATMENT 
PROTOCOLS 
DOSE (Gy) TOTAL DOSE 
(Gy) 
1966 Opposing fields 
Planned field length = 
15cm 
Brachytherapy LDR 
booster or booster plan  
2 
 
 
2 
10 
 
 
30 
1972 Field length (planned 
fields)=12cm 
3 or 
3.5 
57 -60 
42 -45 
1973 – 
1974 
Field length (planned 
fields)=10cm 
  
1975 – 
1990 
Field length (planned 
fields)=8cm 
3 57 - 60 
  
 
In April 1994, the Department of Oncotherapy, Bloemfontein, implemented 
a high dose-rate (HDR) brachytherapy treatment system, an Ir-192 
Nucletron Microselectron afterloading source, using the ring applicator. 
After careful analysis of the available data on fractionation schedules, the 
standard prescribed protocol for treating patients for uterine cervical 
cancer (FIGO stages I-III) was established. The advent of HDR 
brachytherapy in the department, which has the advantages of 
individualised dosimetry, outpatient treatment and elimination of radiation 
exposure of medical personnel, brought a convenient treatment option for 
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patients with uterine cervical cancer, permitting treatment of a large 
number of patients (10-15 patients weekly).  
 
The fractionation schedule applicable to the study is shown in Table 1.4. 
Patients with FIGO stages I-III uterine cervical cancer are treated with a 
combination of EBRT- 2 Gy/fraction x 25 fractions (50Gy to whole pelvis) 
and HDR-ICBT given in 4-6 fractions, once weekly (2 Gy/fraction, 
normalized to the highest rectum dose point), to achieve a minimum total 
dose of 15 Gy to point A, as opposed to the previous protocols mentioned. 
Point A is defined as a geometric point in relationship to the cervical os 
and uterine axis. 
 
Table 1.4 Treatment protocol for FIGO stages I-III cervical cancer 
patients treated at the Department of Oncotherapy, Universitas 
Annex, Bloemfontein, from 1994 up to the time of writing 
EBRT-
Dose per 
fraction 
(Gy) 
EBRT- No. 
of 
fractions 
EBRT-
WholePelvic 
Dose (Gy) 
HDR-
ICBT-
Dose per 
fraction 
(Gy) 
HDR-
ICBT- No. 
of 
fractions 
HDR-ICBT- 
Total dose 
to tumour 
–min.15Gy 
2  25 50 Gy 2  
(2Gy to 
highest 
rectum 
dose 
point) 
4-6  Cumulative 
recorded 
dose to 
point A 
  
  
1.6 High dose-rate brachytherapy 
Since Margaret Cleaves first performed intracavitary brachytherapy for 
cancer of the cervix in 1903, the radiotherapy of cervical cancer has 
traditionally been based on low dose-rate (LDR) intracavitary 
brachytherapy. HDR brachytherapy was developed to overcome some 
potential disadvantages of LDR brachytherapy, especially in the treatment 
of cervical cancer (Ferrigno, Nishimoto, Dos Santos Novaes, Pellizzon, 
Maia, Fogarolli & Salvajoli 2005: 1108). High dose-rate brachytherapy 
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allows for shorter treatment times, resulting in reduced hospitalisation 
costs owing to outpatient therapy, a reduced risk of applicator movement 
during therapy, and a larger throughput of patients in a busy department 
(Nag, Erickson, Thomadsen, Orton, Demanes & Petereit 2000: 202).  
 
Studies reported by Falkenberg, Kim, Meleth, De Los Santos & Spencer 
(2006: 50) and Nag et al. (2000: 202) have compared LDR brachytherapy 
to HDR brachytherapy and have demonstrated comparable local control, 
survival and morbidity. To achieve disease control equivalent to that with  
LDR brachytherapy, changes in the dose/fraction schedule and strict 
attention to normal tissue doses when using HDR brachytherapy are 
mandatory. The biological disadvantage of HDR-ICBT in the treatment of 
cervical cancer is that short treatment times of HDR-ICBT do not allow for 
the repair of non-lethal damage in normal tissue, or the redistribution of 
cells in the cell cycle, or reoxygenation of the tumour cells. Multiple 
treatments are thus required (Nag 2004: 620). These radiobiological 
disadvantages of HDR-ICBT can, however, be overcome through 
adequate fractionation (Nag et al. 2000: 201). 
 
The primary concern of using HDR brachytherapy is a potential late 
toxicity due to large doses per fraction (5 - 9 Gy/fraction). Late responding 
tissues such as the rectum and bladder have a greater capability of repair 
than tumour or early responding tissues, but this repair does not occur as 
fully as that of the same tissues treated with low doses. Fractionation and 
dose adjustments of the total dose are crucial factors in lowering the 
frequency of late radiation complications to the rectum, such as rectal 
bleeding, without compromising the treatment (Patel et al. 2005:125).  
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1.7      Fractionation and dose effectiveness 
Although a large number of fractionation schedules are used worldwide for 
HDR brachytherapy, the optimal schedule has yet to be decided. Petereit 
and Pearcey (1999: 364) analysed the fractionation schedules of 24 
published articles and came to the conclusion that there is no optimal 
fractionation schedule available, but suggested that reasonable 
fractionation schedules should be based on single institutional experience 
with accurate reporting. Members of the American Brachytherapy Society 
(ABS) with expertise in HDR cervical brachytherapy conducted a literature 
review, and, supplemented with their clinical experience and 
biomathematic modeling, formulated guidelines for HDR brachytherapy for 
cervical carcinoma. These recommendations are based on the Patterns of 
Care studies which showed that recurrences and complications  
decreased when brachytherapy was used in addition to EBRT (see 
Literature Review, Nag et al. 2000: 202). The International Atomic Energy 
Agency (IAEA) has also published recommendations specifically for 
implementing HDR, Ir192 brachytherapy in developing countries (Nag et al. 
2002: 298).These recommendations correlate with those of the ABS and 
were thus relevant to the implementation of some of the recommendations 
into the EBRT and HDR-ICBT treatment at the Department of 
Oncotherapy, Bloemfontein. 
 
Although there is a marked variation among institutions in the dose and 
fractionation used for cervical HDR-ICBT, most centers use a schedule of 
approximately 1.8 to 2 Gy per fraction for 25 fractions EBRT and 6-8 Gy 
per fraction for HDR in four to six fractions (Orton, Seyedsadr &  Somnay 
1991: 1425). Analysing different treatment schedules emphasizes the 
need to deliver biologically effective doses of radiation to ensure the 
highest probability of tumour control in the pelvis, because the salvage 
rate in patients who fail with isolated pelvic recurrences are less than 
optimal  even after pelvic exenteration (Perez & Kavanagh 2004: 1858). 
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Consequently, because of a lack of personal or documented experience, 
radiation oncologists frequently resort to the use of bio-effect dose models 
to convert from LDR to HDR (Nag  2004: 610). This is the best available 
model for the quantitative assessment of clinical problems, primarily 
because it allows a distinction to be made between the fractionation and 
dose-rate sensitivities of early and late responding tissues (Clark, 
Souhami, Roman, Chappell, Evans & Fowler 1997: 989). Calculating the 
biologically effective dose to point A using the linear quadratic formula with 
an / of 10 is critical to compare fractionation schedules (Petereit & 
Fowler 2003: 1159). In general, the / values for tumour and early-
responding tissues are approximately 10 (Gy10), and for late-responding 
tissues 3 to 5 (Gy3-5) (Petereit & Pearcey 1999: 360). The values derived 
are not actual doses, but biologically effective ones that take into 
consideration dose-rate and impact of fraction size. 
 
In uterine cervical cancer, the response to radiotherapy is clearly dose-
dependent. As the dose increases, so too does the probability of tumour 
control. However, the risk of damage and late complications in normal 
tissues also increases with the dose (Stewart & Viswanathan 2006: 908). 
The lower the dose-rate of radiation a cell is exposed to, the greater the 
likelihood of repair. Late-reacting normal tissues seem more capable of 
repair than tumours; at a given therapeutic dose, the tumour is 
preferentially killed over normal tissue. The duration of LDR treatment 
(several days) allows for non-lethal damage repair. The short treatment 
time of HDR brachytherapy  prohibits this repair during the actual 
irradiation. However, if an interval of more than 24 hours is maintained, 
normal tissues can undergo full repair. Therefore, LDR may allow recovery 
of more normal tissues during treatment, but HDR may offer the 
advantage of increased cytotoxicity to the tumour (Stewart & Viswanathan  
2006: 909).  
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1.8 Problem statement 
The radiation treatment protocol for carcinoma of the uterine cervix stages 
I-III had to be adjusted at the Department of Oncotherapy, Universitas 
Annex, Bloemfontein, in April 1994 to incorporate HDR-ICBT with EBRT. 
The standard prescribed treatment protocol implemented at Universitas 
Annex since 1994 has thus not been evaluated or analysed for dose 
effectiveness and late radiation complications considering the biologically 
effective dose (BED) administered to cervical cancer patients. As a wide 
range of fractionation schedules exists worldwide with as yet no optimum 
schedule, there is a need to deliver biologically effective doses of 
irradiation to ensure the highest probability of tumour control in the pelvis 
with minimum late rectal complications. 
 
The aim of the current study was to calculate the biologically effective 
dose for the fractionation schedule implemented at the Department of 
Oncotherapy, Universitas Annex, Bloemfontein, since 1994, to determine 
whether the fractionation schedule delivered BED`s that lead to local 
tumour control without severe late rectal complications. These cumulative 
BED`s, calculated for the combination of EBRT and HDR-ICBT, to the 
tumour Gy10 and the rectum Gy3 for cervical cancer patients will enable the 
Department of Oncotherapy, Universitas Annex, Bloemfontein, for the first 
time to compare the fractionation schedule results with those of other 
institutions worldwide.        
 
Analysis of the current treatment schedule, regarding the calculated BED, 
will indicate whether the total dose given to the planned tumour volume 
(PTV) by means of EBRT and the gross tumour volume (GTV) by means 
of HDR-ICBT has led to local tumour control with negligible late toxicity to 
the rectum. 
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1.9      The objectives of the current study 
(i) To analyse the dose effectiveness of the fractionation schedule 
retrospectively by calculating the cumulative biologically effective dose 
(Total BED) of the combination of EBRT and HDR-ICBT for FIGO stages 
I-III uterine cervical cancer patients treated at the Department of 
Oncotherapy, Bloemfontein from January 1998 to  December 2003. 
 
(ii) To analyse retrospectively the incidence of late radiation complications 
as a result of the particular fractionation schedule used, by utilising the 
Radiation Therapy Oncology Group (RTOG)/European Organization for 
Research and Treatment of Cancer (EORTC) grading system, grade 0-5 
(0 means an absence of radiation effects and 5 means the effects led to 
death). See Table 2.2. 
 
 
1.10     The motivation and significance of the study 
As the incidence of cervical cancer is high in developing countries such as 
South Africa it is essential to treat those affected with the best modality 
currently available (Mqoqi et al. 2004: 22). Radiotherapy plays an 
important role in the treatment of carcinoma of the uterine cervix and a 
combination of EBRT and HDR-ICBT is the accepted definitive mode of 
treatment (Patel et al. 2005).  
 
Establishing BED values for the first time to the tumour (Gy10) and the 
rectum (Gy3) by using the LQ model in the fractionation schedule 
applicable to the study will be significant in enabling the Department of 
Oncotherapy, Universitas Annex, to compare the results of this study with 
those reported in the literature worldwide. Whether the BED values 
obtained could be used as a predictor of local tumour control and of rectal 
toxicity in the current treatment protocol for cervical cancer will be 
indicated after statistical analyses have been done. The outcome of the 
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study will thus clearly indicate whether the total dose given to the planned 
tumour volume (PTV) and gross tumour volume (GTV) has been a 
biologically effective dose for local tumour control with negligible late 
toxicity. 
 
Other studies were done on patients with cervical carcinoma at the 
Department of Oncotherapy, Universitas Annex (Friedrich  1996). The 
focus of Friedrich`s study was to calculate LQ (Linear Quadratic) values 
for early and late responding tissues, using larger doses per fraction (3 
Gy). This study will be unique in calculating the cumulative biologically 
effective dose of the fractionation schedule applicable to the study, and 
analysing the tumour control and late radiation complication rate according 
to the cumulative dose and calculated BED for FIGO stages I-III cervical 
carcinoma. 
 
 
1.11 Methodology 
1.11.1 Patient selection 
A list of patients treated with EBRT and HDR-ICBT for cervical cancer 
FIGO stages I-III was obtained from the department’s HDR-ICBT patient 
treatment book. All patient treatment files from 1998-2003 were analysed 
so as to include in this retrospective study only patients with complete 
dosimetric data and a minimum follow-up period of two years.   
 
1.11.2 Calculations 
The linear quadratic model was used to calculate the biologically effective 
doses for all the patients who met the inclusion criteria for this 
retrospective study. It is a mathematically simple way to quantify biological 
responses to different fractionation schedules (Clark et al. 1997: 989).
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1.11.3 Research tool 
A data source form was designed as a research tool to capture the 
relevant data from the patient treatment files (Appendix ). Patient 
demographics, fractionation schedule details, tumour control, late radiation 
complications, metastatic disease and patient survival details were 
obtained from the patients treatment files and follow-up notes.  
 
 
1.12 Data analysis 
The data collected for this retrospective study was processed by the 
Department of Biostatistics, University of the Free State, Bloemfontein. 
Results were summarised by frequencies and percentages (categorial 
variables) and means, standard deviations, minima and maxima 
(numerical variables). The software used was SAS 9.1.3 Service Pack 3. 
 
  
1.13 Ethics 
The proposal for this retrospective study was presented to the Ethics 
Committee at the University of the Free State at the meeting held on 14 
March 2006  and attained the necessary approval. ETOVS NR 31/06. A 
letter of consent (Appendix  ) permitting the use of patient records for the 
retrospective study was obtained from the Head of Clinical Services, 
Universitas Annex. 
 
 
1.14 Outcome of the study 
The results obtained from this study of patients treated for FIGO stages I-
III cervical cancer by using a combination of EBRT and HDR-ICBT are 
applied as follows: 
• Documentation of the biologically effective dose (BED) values for 
future use in treating cervical cancer patients and comparison of the 
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BED values to the tumour Gy10 and rectum Gy3 with those of other 
international institutions. 
• Implementation of  a RTOG/EORTC scoring sheet in the patient follow-
up files for future research on the crude incidence of late radiation 
complications 
• Use of the data to compile a report for a thesis for M.Tech. 
qualification.  
• Presentation of the results of the thesis at congresses and/or 
seminars. 
• Publication of data in relevant medical journals. 
 
 
1.15 Arrangement of the dissertation 
CHAPTER 1: An overview of the study 
This chapter contains an introduction to the relevance of the study, 
incidence of cervical cancer, development of treatment protocols, HDR-
ICBT, fractionation and dose effectiveness, the problem statement, 
objectives, motivation and the outcome of the study. 
 
CHAPTER 2: Literature review 
The literature review covers the epidemiology of uterine cervical cancer, 
staging, radiation therapy, ABS recommendations, biology of HDR 
brachytherapy, time-dose models, treatment techniques, late radiation 
complications and future developments of HDR brachytherapy. 
 
CHAPTER 3: Methodology 
The methodology of the study discusses the methods and materials used 
for patient selection, EBRT, HDR-ICBT insertion technique and treatment 
planning, calculations of the biologically effective dose, the research tool, 
scoring of late radiation complications, statistical analysis and follow-up 
examinations of uterine cervical cancer patients. 
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CHAPTER 4: Results 
The results of the current study are shown in this chapter. The results as 
well as other information gathered by the data source form regarding 
patient selection, patient demographics, tumour characteristics, tumour 
control, metastases and survival are reflected in this chapter. 
 
CHAPTER 5: Discussion and conclusion 
The dose effectiveness and the incidence of late radiation complications of 
the fractionation schedule of EBRT and HDR-ICBT used in treating uterine 
cervical cancer patients at the Department of Oncotherapy, Bloemfontein 
are discussed. 
 
 
1.16 Conclusion 
HDR-ICBT for carcinoma of the cervix is widely used because of its 
advantages over LDR brachytherapy. Although a large number of 
fractionation schedules are in use for HDR-ICBT, the optimal schedule 
has yet to be decided (Patel et al. 2005: 125). Because there are few 
established guidelines for its clinical use the American Brachytherapy 
Society (ABS) formed a committee to issue guidelines specifically for the 
use of HDR-ICBT for cervical carcinoma (Nag et al. 2000: 202). The 
literature review in chapter 2 focuses on these recommendations and 
other published studies regarding the use of EBRT and HDR-ICBT for 
cervical carcinoma.  
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CHAPTER  2 
LITERATURE  REVIEW 
 
 
2.1 Introduction 
Fletcher and his co-workers stated over 55 years ago: “We are still in an 
empirical era in the use of radium therapy in cancer of the cervix” 
(Fletcher, Shalek, Wall & Bloedorn 1952: 935). In the same way, Orton 
(1986) stated 21 years ago that apart from a change from radium to 
cesium, they were still in that empirical era regarding the many 
innovations that have occurred in the use of external beam radiotherapy in 
comparison to the treatment philosophies concerning intracavitary cervix 
treatments. The latter were dictated primarily by tradition and well-
established convention. Unfortunately, there was evidence indicating that 
many of these established conventions were by no means optimal in 
terms of late complications (Orton 1986: 37). Orton also stated that there 
is a temptation to judge treatment “success” by avoiding complications 
rather than by long-term survival. He proclaimed that because 
fractionation and dose rate patterns to the vulnerable pelvic organs vary 
considerably from patient to patient, doses need to be expressed in terms 
of some type of “biologically effective dose” units and not simply Gy (Orton 
1986: 37). 
 
Treating patients who have been diagnosed with uterine cervical cancer in 
the most effective manner requires extensive research of the most recent 
literature on the subject. This literature review scrutinises the appropriate 
evidence supporting the use of HDR-ICBT in combination with EBRT as 
the accepted definite mode of treatment for uterine cervical cancer and 
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correlates it with the dose effectiveness and late radiation complications 
found in the study. This literature study entailed reviewing the relevant 
literature in textbooks and published articles to ascertain the work being 
done in this field and the relevant methods being used. Key words such as 
“HDR brachytherapy” and “uterine cervical cancer” were used to retrieve 
the relevant data from the Internet. The epidemiology of patients 
diagnosed with uterine cervical cancer provides a background to the 
study. 
 
 
2.2  Epidemiology 
The incidence of uterine cervical cancer differs among different population 
groups in South Africa. Since the beginning of the National Cancer 
Registry (NCR) in 1986, uterine cervical cancer has been the leading 
cancer in black women. A total of 5 069 cancers were reported on black 
females in 1998, with 4 342 reported in 1999, comprising, on average, 
about 84% of all uterine cervical cancer cases reported in the two years.  
The second highest rates of 29 per 100 000 and 26.4 per 100 000 in the 
two consecutive years were recorded among coloured women. Asian 
women had the lowest cervical cancer incidence rates of 11 per 100 000 
in 1999. Uterine cervical cancer in white women peaked at a significantly 
lower Age-Specific Incidence Rate (ASIR) of 34.5 per 100 000 and at a 
younger age (60-64) than in black and coloured women where ASIR 
peaked between the ages of 65 and 69 (Mqoqi et al. 2004: 22).  
 
According to Perez (1998) the incidence of uterine cervical cancer is 
substantially higher among women in low socio-economic classes. Uterine 
cervical cancer is more frequent in women who had first sexual 
intercourse at an early age, have a history of sexual promiscuity, or have 
had a large number of pregnancies (Perez 1998: 1734). Considering the 
epidemiology of uterine cervical cancer in South Africa, it is thus of utmost 
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importance to treat women who have been diagnosed with uterine cervical 
cancer with the best curative modality available. 
 
The initial staging system of uterine cervical cancer proposed in 1929 by a 
subcommittee of the League of Nations was revised in 1937 and 1950. 
These functions were taken over by International Federation of 
Gynecologists and Obstetricians (FIGO) in collaboration with the World 
Health Organization (WHO) and the International Union Against Cancer. 
The staging recommendations were last revised in 1995 (Shepherd 1995: 
319). See Appendix  for the FIGO staging classification: Cervical 
Carsinoma. This FIGO staging (being refined e.g. IIIb1R) is used at the 
Department of Oncotherapy, Universitas Annex, Bloemfontein.  The FIGO 
staging system is based on clinical evaluation (inspection, palpation, 
colposcopy), roentgenographic examination of the chest, kidneys, and 
skeleton, and endocervical curettage and biopsies. 
 
Different stages have different local control outcome as indicated by a 
study done by Patel et al. (Patel et al. 2005: 125). They reported on 121 
patients with stages I-III uterine cervical cancer who were treated with 
EBRT and HDR-ICBT. The actuarial local control rate at 5 years was 
100% for stage I, 80% for stage II and 67,2% for stage III uterine cervical 
cancer patients. Toita et al. (2003) also stated that in their study on uterine 
cervical cancer patients treated with EBRT and HDR-ICBT, the 5-year 
local control rate for stage II was 87% and stage III was 50% (Ferrigno et 
al. 2005: 1113). Thus it seems as if the local tumour control of a patient 
diagnosed with uterine cervical cancer is influenced by the FIGO staging. 
The probability of rectal complications shows a correlation for dose-
response, while clinical stage is not associated with increased risk of late 
rectal sequalae (Chen, Liang, Yeh, Yang, Shiau & Lin 2004: 667). 
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2.3    Radiation therapy 
Since the introduction of the first remote afterloading machine in 1962, 
designed by Rune Walstam at the Radiumhemmet in Stockholm, with a 
three 50 mg and one 9 mg radium tubes, modern brachytherapy 
techniques of afterloading and dosimetry optimisation have made 
revolutionary strides in treating cancer patients (Mould, Batterman, 
Martinez & Speiser 1994: 8).  
 
Radiation therapy of uterine cervical cancer patients has traditionally been 
based on low dose-rate (LDR) intracavitary brachytherapy for almost 100 
years. However, concerns about its disadvantages, such as the  exposure 
of medical staff to radiation, prolonged treatment time, risk of applicator 
movement and mandatory hospitalisation, led to the development of HDR 
brachytherapy (Shakespeare, Lim, Lee, Back, Mukherjee & Lu 2006: 277). 
Because of the high incidence of uterine cervical cancer in developing 
countries, it is the most common indication for gynecological 
brachytherapy and can account for up to 100% of the brachytherapy 
practice (Nag et al. 2002: 298). Due to the short treatment times needed, 
HDR machines are capable of treating larger numbers of patients than 
LDR techniques. The shorter treatment times of HDR brachytherapy also 
reduce the risk of applicator movement and reduce hospitalisation costs 
because of using outpatient therapy instead. Additionally, in HDR 
brachytherapy, late tissue complications might be minimised more 
effectively than in LDR brachytherapy, because greater normal tissue 
displacement (e.g. bladder anteriorly and rectum posteriorly) is possible 
because of the short treatment times and available retraction devices (Nag 
et al. 2000: 202).  
 
Other advantages of HDR-ICBT treatment include eliminating  radiation  to 
care givers and visitors. HDR brachytherapy also eliminates the need for 
source preparation and transportation and because there is only one 
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source, there is minimal risk of losing a radioactive source (Nag 2004: 
620). HDR sources are of smaller diameter than the cesium sources that 
are used for intracavitary LDR brachytherapy and therefore reduce the 
need for dilatation of the cervix, thus reducing the need for heavy sedation 
or general anesthesia. HDR brachyhterapy also improves treatment dose 
distribution optimisation. Technical advances in HDR brachytherapy and 
its advantages over LDR brachytherapy made this treatment modality, in 
combination with EBRT, an essential component of the curative treatment 
of uterine cervical cancer (Nag et al. 2002: 299). 
 
 
2.4 Recommendations of the American Brachytherapy Society (ABS) 
A literature analysis was done by Petereit et al. (1999) of the University of 
Wisconsin, USA, on the fractionation schedules of 24 articles published 
using the linear quadratic model to determine if doses can be correlated 
with local control and complications. Their conclusion was that a dose 
response relationship could not be identified for tumour control or late 
tissue complications, mainly because most of the HDR publications 
reported inadequate details of the dose fractionation schedules. It was 
also reported that the optimal fractionation schedule for treating uterine 
cervical cancer using HDR brachytherapy is still unknown, and presently 
can be based on single institutions with significant experience (Petereit, 
Sarkaria, Potter & Schink  1999: 359). 
 
In order to address this problem, in 2000, the American Brachytherapy 
Society (ABS) published recommendations regarding the treatment of 
patients diagnosed with uterine cervical cancer with fractionation schemes 
which utilises the combination of EBRT and HDR-ICBT (Nag et al. 2000: 
202). A retrospective study was done by Shakespeare et al. (2006) to 
assess the suggested ABS guideline tolerability in an Asian population. 
The study indicated good local control and survival outcomes. The 
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conclusion of the study was that it is reasonable and safe to follow the 
guidelines laid out by the ABS (Shakespeare et al. 2006: 281). The 
following are some recommendations and guidelines given by the ABS: 
 
 General recommendations 
The ABS recommends that brachytherapy be included as a component of 
the definitive radiation therapy for uterine cervical carcinoma, based on 
the Patterns of Care studies that show that recurrences and complications 
are decreased when brachytherapy is used in addition to EBRT (Nag et al. 
2000: 202). Nag et al. reported that the relative doses given by EBRT 
compared to brachytherapy depend upon the initial volume of disease, the 
ability to displace the bladder and rectum, the degree of tumour regression 
during pelvic irradiation and institutional preference. Patients with larger 
tumour volumes receive 20-30 Gy of EBRT before HDR-ICBT treatment is 
initiated to allow for tumour shrinkage of tumor and a more favourable 
anatomic geometry for applicator placement. Because the overall 
treatment duration would be unduly prolonged if HDR treatments were 
begun after completion of EBRT, the HDR-ICBT is interdigitated during the 
course of EBRT. However, EBRT is not given on the day of a HDR-ICBT 
treatment. Typically, if the vaginal geometry is optimal, HDR 
brachytherapy begins after 2 weeks of EBRT. HDR-ICBT is given once a 
week, with the EBRT continued on the other four days of the week. These 
recommendations have been implemented at the Department of 
Oncotherapy, Universitas Annex, Bloemfontein. 
 
 External beam radiotherapy 
The ABS recognises that the whole pelvic EBRT dose varies from 
institution to institution. The HDR fraction size and number depends on the 
EBRT dose (Nag et al. 2000: 203). Some institutions prefer to limit the 
whole pelvis dose for patients with early disease and to perform the first 
intracavitary insertion after 20 Gy, with further EBRT delivered with a 
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central block in place. If a lower EBRT dose is chosen for patients with 
early disease, the ABS recommends increasing the HDR fraction size and 
number of fractions. However, the individual fraction size should be kept to 
less than 7.5 Gy due to reports of higher toxicity with larger fractions. Most 
institutions, which include the Department of Oncotherapy, Bloemfontein, 
prefer to deliver 40-50 Gy of EBRT to the entire pelvis. In these cases, the 
brachytherapy dose is decreased. If EBRT doses greater than 45-50 Gy 
are to be given, the treatment fields should be coned down after the initial 
45-50 Gy in an effort to exclude small bowel (Nag et al. 2000: 203).  
 
Dose specification 
Ideally, the dose should be prescribed to the individual patient`s target 
volume. Unfortunately, many facilities lack the capability to determine the 
volume at risk, nor is there sufficient information in the literature to 
establish a better delineated target volume than the customary, 
Manchester System defined Point A. For HDR brachytherapy, the ABS 
has provided an applicator-based definition of point A that has been 
named point H (Nag et al. 2000: 204). Point H was created by the ABS to 
standardise the dosimetry process in the computerised treatment planning 
era by defining point A in relation to the applicator as seen on radiographs, 
as apposed to the cervical os. 
 
Dose recommendations 
The ABS recommends that the goals are to treat uterine cervical cancer 
with a combined EBRT and HDR dose to point A, to at least a total LDR 
equivalent of 80-85 Gy for early stage disease and 85-90 Gy for advanced 
stage disease (Nag et al. 2000: 201-211). The pelvic sidewall dose 
recommendations are 50-55 Gy for early lesions and 55 -65 Gy for 
advanced ones. Every attempt should be made to keep the bladder and 
rectal doses below 80 Gy and 75 Gy LDR equivalent doses, respectively. 
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While recognizing that many efficacious HDR fractionation schedules 
exist, the ABS has developed suggested tables for combining the EBRT 
with HDR brachytherapy for patients with early and advanced stages of 
uterine cervical cancer, respectively (Table 2.1) (Nag 2004: 621). 
Table 2.1       ABS suggested doses of EBRT and HDR-ICBT  
                      (Nag 2004: 621) 
EARLY STAGE ADVANCED STAGE 
EBRT (Gy) 
at 1.8 
Gy/fraction 
No. of 
HDR 
fractions 
HDR 
Dose 
per 
fraction 
(Gy) 
EBRT (Gy) 
at 1.8 
Gy/fraction 
No. of 
HDR 
fractions 
HDR 
Dose 
per 
fraction 
(Gy) 
19.8 6 7.5 45 5 6.5 
19.8 7 6.5 45 6 5.8 
19.8 8 6 50.4 4 7.0 
45 5 6 50.4 5 6.0 
45 6 5.3 50.4 6 5.3 
 
Treatment schedules integrating external beam radiation therapy and 
brachytherapy were initially designed with regard to the disease stage and 
volume (Perez & Kavanagh 2004: 1840). In most centers, as the tumour 
volume or stage increases, the external beam dose plays a more 
prominent role in the total dose, whereas the number of HDR fractions and 
the dose per HDR fraction are decreased. 
 
Although there is a marked variation in the dose and fractionation used for  
cervical HDR-ICBT, most centers use a schedule of approximately 1.8/2 
Gy per fraction for 25 fractions EBRT and 6-8 Gy per fraction in four to six 
fractions (Orton et al. 1991: 1425). The fractionation schedule applicable 
to this retrospective study, used at the Department of Oncotherapy, 
Bloemfontein, is 2Gy/fraction for 25 fractions of EBRT and a dose of 2 Gy 
prescribed to the highest rectum dose point, administered in 4-6 fractions 
of HDR-ICBT. The dose to point A varies for each HDR-ICBT treatment 
given as a result of the changes in the rectum position for each treatment. 
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The standard prescribed protocol for the HDR-ICBT treatment requires a 
minimum total dose of 15 Gy to point A, achieved in 4-6 fractions. 
 
 
2.5 Dose effectiveness of fractionation schedules 
The use of HDR brachytherapy initially faced criticism and concerns with 
regard to its effectiveness and late toxicity. However, over the past few 
years, numerous published studies have demonstrated comparable local 
control, survival and morbidity with HDR when compared with LDR 
(Shakespeare et al. 2006: 278). A study on HDR vs. LDR by Falkenberg 
et al. (2006) confirmed equivalence in pelvic control, cause-specific 
survival and overall survival, as well as late morbidity between LDR and 
HDR brachytherapy (Falkenberg et al. 2006: 54). The following are some 
results reported in the literature on the clinical outcome of different 
institutions when using HDR-ICBT in combination with EBRT in their 
treatment schedule for uterine cervical cancer patients. 
 
In 1991, Lanciano et al. (1991) reported their findings on pre-treatment 
and treatment factors associated with improved outcome in squamous cell 
carcinoma of the uterine cervix (Lanciano, Won & Coia 1991: 667-676). 
Lanciano et al. (1991) compared the outcome of the 1973 and 1978 
Patterns of Care surveys. It indicated that on 1558 patients treated using 
EBRT with or without low dose-rate brachytherapy at different institutions 
throughout the United States, no dose-response relationship was seen to 
a dose at point A of < 75, 75-85, or > 85Gy in stage I and II disease. 
Although a dose-response relationship was seen with a dose > 85 Gy in 
stage III disease, a dose > 85 Gy was also associated with higher rate of 
complications. 
 
A retrospective study was done by Chen et al. (2000) to see whether     
patient, treatment and dosimetric factors could be correlated to the risk of 
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developing late rectal complications in patients with uterine cervical 
cancer. The fractionation schedule consisted of EBRT of 40-44 Gy/20-22 
fractions given within 4-5 weeks to the whole pelvis, after which the dose 
was boosted up to 54-58 Gy with central shielding. HDR-ICBT consisted 
of 3-4 insertions at doses of 5-7.2 Gy and the cumulative rectal biologic 
equivalent dose was calculated. The study indicates that patients who 
have stages IIb-IVa disease, a cumulative rectum dose greater than 65 
Gy, or who are of 70 years of age and older, are at risk for late rectal 
sequelae and should be adequately assessed so that the treatment dose 
can be adjusted to prevent late rectal complications (Chen, Liang, Yang, 
Liu & Lin 2000: 960). 
 
The Brazilian Experience of Ferrigno et al. (2001) is based on the analysis 
of dose effectiveness and late radiation complications. One hundred and 
thirty-eight patients with FIGO stages II and III were treated with 45 Gy of 
EBRT in 25 fractions and HDR brachytherapy was performed during 
EBRT with a dose of 24 Gy in 4 weekly fractions of 6 Gy to point A. The 
overall survival, disease-free survival and local control at 5 years was 
53.7%, 52.7%, and 62%, respectively. The five-year actuarial incidence of  
rectal, bladder and small bowel late complications was 16%, 11% and 
14%, respectively. Patients treated with a cumulative BED at rectum 
points above 110 Gy3 had a higher but not statistically significant five-year 
actuarial rate of complications at these organs (Ferrigno, dos Santos, 
Pellizon, Maia, Fogarolli, Gentil & Salvajoli  2001: 1123). 
 
Sood et al. (2002) reported on the predictive value of the linear
 quadratic model in the treatment of cervical cancer using HDR
 brachytherapy. In this retrospective study 49 patients were treated with
 EBRT of 45 Gy (1.8 Gy/fraction) to the whole pelvis and HDR-ICBT
 consisting of a total of 18-19 Gy given in 2 fractions of 9-9.5 Gy.
 Twenty-three patients received concomitant cisplatin-based
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 chemotherapy. The report indicated that in patients treated with
 radiotherapy alone, a BED10>89 Gy indicated a trend toward a better
 local control rate. This difference was not observed in patients
 receiving chemotherapy. A BED3<100 Gy3 was associated with
 negligible late toxicity. The 4-year local control rate was 80% and 83%
 and disease-free survival rate of 75% and 70% with and without
 chemotherapy, respectively (Sood, Garg, Advadhani, Gorla, Malhotra,
 Guha, Deore  & Vikram  2002: 1377) 
 
Another analysis was performed by Toita et al. (2003) on dose 
effectiveness and fractionation schedule. Eighty-eight patients with 
cervical cancer were treated with EBRT of 2 Gy/fraction to a total dose of 
40 Gy, and HDR-ICBT was performed once a week with a total point A 
dose of 18 Gy. The three-year actuarial pelvic control rate was 82% for all 
88 patients: 96% for early stage and 76% for advanced disease. No 
significant dose-response relationship was observed by the treatment 
schedule and cumulative BED at point A for both early and late disease. 
All patients treated with 86.4 Gy10 at point A suffered both proctitis and 
enterocolitis. Patients with cumulative BED at rectal point  100 Gy3 had a 
significantly higher incidence of proctitis (Toita, Kakinohana, Ogawa, 
Adachi, Moromizato, Nagai, Maehama, Sakumoto, Kanazawa  & 
Murayama  2003: 1344). 
 
The report published by Wang et al. (2004) compared two linear quadratic 
model-based iso-effect fractionation schemes of HDR brachytherapy for 
cervical cancer. Five hundred and forty-one women were categorised into 
two groups according to the two iso-effect schemes used. Group 1 
consisted of 254 patients treated with EBRT plus 7.2 Gy HDR-ICBT to 
point A for three fractions. Group 2 consisted of 284 patients treated with 
EBRT plus 4.8 Gy HDR-ICBT for five fractions. Overall, 66 patients 
developed pelvic recurrence. Of these, 53 patients had central recurrence: 
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24 (9.4%) were in group 1 and 29 (10.1%) in group 2. The actuarial 
survival rate for Groups 1 and 2 was 63.5% and 56.1% at five years and at 
ten years 47.8% and 49.3%, respectively. The incidence of high-grade 
complications remained unchanged, 8% vs. 7%. Multivariate analysis 
revealed that the fractionation scheme (three fractions vs. five fractions) 
was a significant factor influencing the proctitis rate, but not the local 
pelvic control rate, overall survival rate, or cystitis rate. The report 
concluded that the treatment results of the two groups showed similar 
outcomes while the complications decreased, and that the linear quadratic 
model correctly predicted the outcome. Biologically, the manipulation of 
the fraction size in their study suggested that the sensitivity of the late 
responding tissue to the fractional change from 7.2 Gy to 4.8 Gy in HDR-
ICBT is high and detectable clinically (Wang, Huang, Sun, Chen, Fang, 
Hsu, Changchien & Leung 2004: 179). The cumulative BED for these 
published studies correlates well for local tumour control Gy10 (range: 80-
100 Gy10) and for negligible late toxicity Gy3 (range: 100-120 Gy3). 
 
Although HDR brachytherapy has been used for more than 30 years in the 
treatment of uterine cervical cancer, the optimal time, dose and 
fractionation have yet to be established through systemic clinical trials 
(Sood et al. 2002: 1377). Toita et al. also stated that an optimum 
treatment schedule has not yet been clearly determined (Toita et al. 2003 : 
1344). Regarding the results reported by all the above-mentioned authors 
on dose effectiveness of the different fractionation schedules for EBRT 
and HDR-ICBT, it is still unclear as to which schedule is the optimum 
fractionation schedule.  
 
 
2.6      Biology of HDR brachytherapy 
The primary disadvantage of HDR brachytherapy is of radiobiological 
concern. The high dose-rate leading to short treatment times does not 
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allow for the repair of non-lethal damage in normal tissue, or the 
redistribution of cells in the cell cycle, or re-oxygenation of the tumour 
cells; hence, multiple treatments are required (Nag 2004: 620). The 
radiobiological disadvantage can, however, be overcome through 
adequate fractionation, e.g. 4/5 fractions of 2 Gy/fraction prescribed to the 
highest rectum dose point, which is the treatment protocol used in this 
retrospective study.  
 
Radiobiologically, the change from low dose rates to HDR requires a   
reduction in overall dose and the introduction of fractionation. 
Fractionation introduces logistic problems for brachytherapy because 
multiple treatment exposures of HDR radiation, 24 hours apart, require 
either repeat implant procedures or a very stable, carefully verified implant 
remaining in situ for the duration of the fractionated treatment. Appropriate 
dose reductions have also been required, and the considerable range of 
schedules used for HDR brachytherapy reflects the uncertainty in this area 
(Hoskin & Bownes  2006: 209). 
 
To achieve tumour control with HDR equivalent to that with LDR 
brachytherapy, attention to the dose/fraction schedule and to normal 
tissue doses is mandatory. In general, the / values for tumour and early-
responding tissues are approximately 10 (Gy10) and for late-responding 
tissues 3-5 (Gy3-5). The values derived are not actual doses but 
biologically effective ones that take into consideration dose-rate and 
impact of fraction size (Perez & Kavanagh 2004: 1839). 
 
Figure 2.1 illustrates late damage, which is proportional to log cell kill, and 
the relationship of late damage to the number of HDR treatment fractions. 
Each full curve is calculated assuming the same log cell kill. Late damage 
rises sharply as the number of HDR fractions is decreased. When these 
curves are above the dashed lines that represent the maximum late effect 
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of 70 Gy of LDR brachytherapy given at 0.5 Gy/h, the risk of late 
complications increases. Displacing the bladder and rectum away from the 
HDR sources for the short duration of brachytherapy can offset the 
radiobiological disadvantage of using a few brachytherapy fractions (Perez 
& Kavanagh 2004: 1839). 
 
Figure 2.1     Relationship between number of HDR fractions and  
late normal tissue effects (Perez & Kavanagh 2004: 
1839). (Permission to use above figure has been duly 
granted.) 
 
Each center has developed unique HDR treatment schedules, dose 
specification systems and time-dose fractionation protocols that reflect 
their understanding of radiobiological issues and their patient population 
base (Perez & Kavanagh 2004: 1840). To achieve tumour control with 
HDR equivalent to that with LDR brachytherapy, attention to the 
dose/fraction schedule and to normal tissue doses is mandatory (Hall & 
Brenner 1991: 1403). An analysis of 1 054 patients showed that patients 
exhibiting complete tumour regression within 30 days after completion of 
radiation therapy had not only a substantially lower number of pelvic 
recurrences but fewer distant metastases (Perez & Kavanagh 2004: 
1858). The analysis emphasises the need to deliver biologically effective 
doses of irradiation to ensure the highest probability of controlling the 
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tumour in the pelvis because the salvage rate in patients who present with 
isolated pelvic recurrences is not optimal even after pelvic exoneration. 
 
In parallel with the technical developments in intracavitary brachytherapy, 
advances have been made in the understanding of how tissues respond 
when altered by radiotherapy treatments. Work in the field of radiobiology 
has produced mathematical models which attempt to predict the response 
of tissues to changes in treatment (Deehan & Donoghue 1994: 21). 
 
 
2.7 Time-dose models 
Various formulas for the comparison and effectiveness of different 
radiation regimes have been developed with clinical experience as 
guideline. These formulas were an attempt to quantify the influence of 
dose fractionation, dose-rate and total treatment time on tolerance doses 
of various normal tissues (Ellis 1969: 2). Early iso-effect models such as 
the Nominal Standard Dose (NSD), Time Dose Factors (TDF) or the 
Cumulative Radiation Effect (CRE) models, which did not distinguish 
between acute and late reactions, have given way to a more sophisticated 
formulae, for example, the linear quadratic (LQ- model) (Fowler 1992: 16-
21). 
 
Since the 1980`s the NSD approach has been largely replaced by the LQ 
approach, which is based on a biophysical model relating cellular survival 
to absorbed dose (Williamson & Brenner 2004: 520). These new models 
reflect the fact that different tissues react in different ways to changes in 
treatment schedules. The LQ model has proved to be a reliable means of 
comparing different schedules in both fractionated and continuous 
radiotherapy (Deehan & Donoghue 1994: 21). This is the best available 
model for the quantitative assessment of clinical problems, primarily 
because it allows distinction to be made between the fractionation and 
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dose-rate sensitivities of early and late responding tissues (Clark et al. 
1997: 989). 
 
The linear quadratic model, originally applied to fractionated radiotherapy 
by Fowler and Stern in 1960, was refined and expanded by Barendson in 
1982 and Dale in 1985, and its use has been reviewed by Fowler (Fowler 
1992: 16). The basic equation defines the amount of radiation damage, E, 
resulting from n high dose-rate fractions of size d - equation 1: 
  d 
 E = n (d + d2) 
 
where two coefficients,  and  are constant and their ratio, /, is an 
inverse measure of fractionation sensitivity or recovery capacity, 
characteristic of a particular tissue (Clark et al. 1997: 990). The 
biologically effective dose (BED) is defined by the equation 2: 
      d 
BED = E/ = nd ( 1+ / 
 
In general, the / values for tumour and early-responding tissues is 
approximately 10 (Gy10), and for late-responding tissues 3 to 5 (Gy3-5) 
(Petereit & Pearcey 1999: 360). The values derived are not actual doses, 
but biologically effective ones that take into consideration dose-rate and 
impact of fraction size.  
 
The dose effectiveness in this study is analysed retrospectively according 
to the calculated BED values of the combination of EBRT and HDR-ICBT 
for FIGO stages I-III uterine cervical cancer patients.  In the determination 
of total BED, the EBRT and HDR-ICBT components have been summed 
with all calculations using the same value of the ratio /. The BED values 
to the tumour Gy10 and the rectum Gy3 is calculated by using the LQ-
model. 
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For a prescribed tumour dose of 46 Gy EBRT in 23 fractions and 30 Gy 
HDR-ICBT in 3 fractions, the total BED to the tumour corresponds to 115 
Gy10 where the subscript is the value of / used in the calculation, 
emphasising that, although the dimensions are those of dose, this value is 
an effective dose rather than an absolute dose. If the rectal reference 
point also received the prescribed tumour dose, the total BED to this point 
would be 207 Gy3, reflecting that in this tissue, the response is 
characterised by an / of 3 Gy. The variation in the dose received at the 
rectal reference point amongst the 43 patients analysed in a study arose 
almost entirely from the HDR-ICBT insertions as a result of variation in 
individual anatomy (Clark, Souhami, Roman & Evans 1994: 1243-1250). 
  
According to the LQ model, the natural logarithm of cell-surviving fraction 
of cells irradiated at a dose-rate R (Gy hr) in time t (hours) is given by the 
formula: ln S =  (Rt) + G (Rt), where  and  are parameters that present 
the probabilities of irrepairable (-type) and repairable (-type) damage. 
The parameter G signifies the reduction in -type damage resulting from 
repair during or immediately after an exposure. Rearranging this equation 
and dividing both sides by  leads to the formula for the biologically 
effective dose (BED), where the single parameter / represents the 
curviness of the log cell-survival curve. The / parameter indicates the 
sensitivity of a given tumour or organ to changes in dose per fraction or 
dose-rate. The parameters  and  (the linear and quadratic sensitivity 
coefficients in the LQ equation) respectively determine the initial slope and 
degree of downward curvature of the underlying cell survival curve (Joiner 
& van der Kogel 1993: 106-122). A cell-survival curve with a large 
curvature means that the dose in the equation mentioned is very 
important. If,  is relatively high, the / is low. This is typical of late-
responding normal tissue cells, for which / values are usually in the 
range of 1 to 4 Gy (Nag 2004: 610). However, if the log cell-survival curve 
is fairly straight, -type damage predominates and / is large. This is 
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typical of tumour and early responding normal tissue cells, for which / 
values are usually in the range of 5 to 20 Gy. 
 
 
2.8 Treatment techniques and dose specifications 
Based on clinical experience, different systems have been proposed for 
the treatment of uterine cervical cancer. Three basic systems have been 
developed: the Stockholm system (Kottmeier, 1964), the Paris system 
(Lamarque and Coliez, 1951) and the Manchester system (Patterson, 
1948). 
 
At the Department of Oncotherapy, Bloemfontein, the HDR-ICBT planning 
is based on the Manchester system to treat patients diagnosed with 
uterine cervical cancer. The Manchester system (Patterson & Parker 
1934) derived from the original Paris system, initiated in about 1920, was 
designed to deliver a constant dose to defined points near the cervix, 
irrespective of variation in size and shape. An application was specified in 
terms of the “dose” in roentgens delivered at specific points such as point 
“A” and “B” Figure 2.3.  
 
Figure 2.2  Manchester system definition of points “A” and ”B” 
                       (ICRU 1985: 2). 
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Originally point A was defined as a point 2 cm superior to the lateral 
vaginal fornix and 2 cm lateral to the cervical canal. It was later redefined 
as 2 cm superior to the external cervical os (or cervical end of the tandem) 
and 2 cm lateral to the cervical canal. Points “A” and “B” are still widely 
used throughout the world, although their exact meaning and their 
definition have not always been interpreted in the same way in different 
centers and even in a given center over a period of time. The International 
Commission on Radiation Units and Measurements (ICRU 1985: 2) 
defines point A as 2 cm lateral from central canal of the uterus and 2 cm 
superior from the mucous membrane of the lateral fornix of the cervix, in 
the axis of the uterus. Point B is defined in the transverse axis through 
point A, 5 cm from the midline (3 cm lateral from point A (ICRU 1985: 2). 
 
In particular, some centers relate point A to anatomical references in the 
patient, others to the geometry of the sources. At the Department of 
Oncotherapy, Bloemfontein, treatment planning of HDR-ICBT is done by 
prescribing 2 Gy/fraction to the highest rectum dose point and normalising 
it to point “A” which is an anatomical reference point in the patient. Thus 
the dose to clinical points A would vary as a function of the distance to the 
maximum rectum dose point. The standard prescribed protocol for this 
study for HDR-ICBT was a minimum total dose of 15 Gy to point A in 4-6 
treatments of 2 Gy/fraction. Point A is defined as a point 2 cm lateral to the 
central canal of the uterus and 2 cm superior from the mucous membrane 
of the lateral fornix, in the axis of the uterus. 
 
Computer-generated isodose curves provide the best means of 
determining the doses to point A, point B, bladder and rectum. The rectum 
position of every fraction given will thus determine the dose to point A for 
each treatment fraction. Special attention should be paid to obtaining as 
symmetrical and homogenous dose distribution as is technically allowed 
by the geometry of the cervix/vagina and the configuration of the tumour 
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with the use of a rectal retractor in the vagina. Computerised optimisation 
of source position and the dwell time for each position is an advantage of 
HDR brachytherapy in that it  can provide customised treatment planning 
on a case-by-case basis. Achieving an optimal dose distribution with HDR-
ICBT requires both accurate insertion of the appliance and accurate 
optimisation. It should be realized that incorrect optimisation is worse than 
no optimisation at all (Nag et al. 2000: 205). The advantages of computer-
aided planning at ICRU reference points are that calculations are available 
before HDR-ICBT treatment and that they can still be taken into account 
for treatment planning (ICRU 1985: 5). The ICRU made the 
recommendation for absorbed-dose patterns and volumes that information 
should include type of applicator used during brachytherapy, type of 
source, how it was loaded and the verification film of the application. 
 
With HDR-ICBT treatment the dose is at its maximum adjacent to the 
source and at the centre of the treatment volume and it falls off 
continuously with distance from the sources. Consequently, the size of the 
treatment volume cannot be deduced from a simple inspection of the 
isodose pattern. Therefore, the radiotherapist has to indicate which dose 
level defines the treatment volume (ICRU 1985: 5). 
 
Assuming that the Manchester definition of point A is used, this will be the 
location where there is least variation in the dose-rate from one source 
arrangement to another one. In the classical Manchester system, point A 
is defined (as previously mentioned) as a point 2 cm lateral to the central 
canal of the uterus and 2 cm superior from the mucous membrane of the 
lateral fornix, in the axis of the uterus. In clinical practice, dose 
calculations are often made from radiographs and point A is taken 2 cm 
superior from the flange of the intra-uterine source and 2 cm lateral from 
the central canal as indicated in Figure 2.3 (ICRU 1985: 2).  
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2.9       Late complications of organs at risk 
Organs at risk are those radiosensitive organs in or near the target volume 
that would influence treatment planning and/or the prescribed dose. In an 
intracavitary application for uterine cervical cancer, the main organs at risk 
are the rectum, bladder, ureters and possibly sigmoid colon (ICRU  1985: 
8). 
 
The sites of radiation-related complications which are most frequently 
noted in uterine cervical cancer radiotherapy are: (a) rectum – the anterior 
rectal wall most commonly; (b) bladder – the posterior bladder wall most 
commonly; (c) vaginal vault; (d) sigmoid colon; (e) small bowel – the 
terminal ileum or multiple sites may be affected; (f) abdomen – diffuse 
multistructure problems may be encountered; (g) ureters – stenosis my 
occur in the paracervical region; (h) skin and (i) bone and hip (Maruyama, 
Van Nagell, Utley, Vider & Parker 1974: 700). In each of these sites, 
advancing tumour stage greatly increases the likelihood of complications. 
It is difficult to define tolerance dose when a combination of external and 
brachytherapy is used. Although stage, age and other disease will 
naturally modify the number and frequency of complications, it should be 
expected to increase as a function of delivered dose (Maruyama et al. 
1974: 700). 
 
Rectal complications have long been the major concern when applying 
radiation therapy to treat patients with uterine cervical cancer. Efforts are 
underway to determine the dose to the rectum to reduce the incidence of 
such complications. However, the risk analysis of rectal complications is 
difficult because of the variations in the combined EBRT and HDR-ICBT, 
the multitude of dosimetric descriptions and the complexity of the 
anatomy. The highly inhomogeneous dose distribution within the pelvis 
renders the definition of certain doses difficult, and reliable estimates of 
tolerance levels have not been established. The distance between the 
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applicators and the recto-sigmoid region may vary with each insertion as a 
result of individual technical skills and various motilities of the bowel 
(Cheng, Peng, Chen, Huang, Wu & Jian 2003: 1016). 
 
The ICRU Report 38 recommends a reference point for specification of the 
absorbed dose to the rectum (ICRU 1985: 11). According to the ICRU 
report the rectal reference point is defined in the lateral projection of the 
applicators on an AP line drawn from the distal end of the uterine source 
or the middle of the ovoid sources. However, several authors have 
demonstrated the maximal rectal dose points to be located at positions 
other than the ICRU reference point. 
 
Chung et al. calculated both the maximal rectal dose to the anterior rectal 
mucosa identified by contrast medium and the ICRU reference rectal 
dose. They obtained a significant relationship between the occurrence of 
late rectal complications and both types of rectal doses. The maximal 
rectal point dose estimated by contrast medium was greater and 
correlated better with late complications than did the strictly defined ICRU 
rectal dose (Chung, Kim & Suh 1996: 319). Therefore the maximal rectal 
dose point estimated by contrast medium is used at the Department of 
Oncotherapy, Bloemfontein. 
 
Cheng et al. reported in 2003 on the unique role of the proximal rectal 
dose in late complications for patients with uterine cervical cancer 
undergoing HDR-ICBT in combination with EBRT. They concluded that 
the radiation dose to the proximal rectum plays a more prominent role in 
predicting late rectal complications in patients with uterine cervical cancer 
undergoing HDR-ICBT. The importance was established by the greater 
dose at the proximal rectal point, as estimated by use of rectal contrast 
medium, than at the ICRU reference rectal point in 89% of patients. The 
use of contrast medium to delineate the rectal wall up to rectosigmoid 
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level should be emphasised. Cheng et al. (2003) recommend rectal dose 
constraints of  62 Gy in the direct sum of EBRT dose and HDR-ICBT,  
110 Gy for the BED, and a maximal rectal dose/point A dose ratio of  0.9 
(Cheng et al. 2003: 1016). 
 
To evaluate the crude incidence of late complications of organs at risk 
after radiotherapy, the Late Morbidity Scoring Criteria were developed as 
a joint effort between physicians with renewed interest in fast neutron 
therapy and Radiation Therapy Oncology Group (RTOG) staff. 
Investigators from the European Organisation for Research and Treatment 
of Cancer (EORTC) wished to have common toxicity criteria in anticipation 
of joint studies. RTOG Protocol 7929, an international registry of patients 
treated with heavy particles, was started in 1980. Winchester and Cox 
published an abbreviated version of the RTOG/EORTC toxicity criteria in 
1992 (Cox, Stetz & Pajak 1995: 1341). Table 2.2 shows the 
RTOG/EORTC Late Radiation Morbidity Scoring Scheme which will be 
used in this retrospective study to grade the late radiation complications of 
organs such as the rectum and the bladder of uterine cervical cancer 
patients.  
Table 2.2 Crude incidence of late complications according to 
                      RTOG/EORTC-late radiation morbidity scoring scheme 
                      (Cox et al. 1995) (0 means an absence of radiation effects 
                      and 5 means the effects led to death) 
    
 SITE    RECTUM 
GRADE 0   None 
 GRADE 1   Increased stool frequency, 
     Occasional blood-streaked stool, or 
     Rectal discomfort (including haemorrhoids) 
 GRADE 2   Increased stool frequency, 
     Bleeding, mucus discharge, or 
     Rectal discomfort and anal fissure 
 GRADE 3   Increased stool frequency/diarrhoea, 
     Rectal bleeding, mucus discharge 
 GRADE 4   Perforation, bleeding or necrosis 
     Or other life-threatening complication 
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 SITE    BLADDER 
 GRADE 0   No change from baseline 
 GRADE 1   Slight epithelial atrophy/minor 
     Telangiectasia (microscopic haematuria) 
 GRADE 2   Moderate frequency/ 
     Generalised telangiectasia/ 
     Intermittent macroscopic haematuria 
 GRADE 3   Severe frequency and dysuria/severe 
     Generalised telangiectasia; frequent 
     Haematuria; reduction in bladder capacity 
 GRADE 4   Necrosis/contracted bladder/ 
     Severe hemorrhagic cystitis 
 
 
2.10 Future developments 
The dramatic advances in technology in the last 2 decades have impacted 
on the practice of brachytherapy in 2 main areas; viz. treatment delivery 
and treatment planning.  
 
Changes in brachytherapy treatment delivery have evolved partly through 
changes in the source availability and through a wide-spread move from 
manual systems to remote afterloading brachytherapy systems. In 
developed countries, radium is no longer used, and cesium sources are 
increasingly being decommissioned to be replaced by high dose-rate 
(HDR) iridium 192 afterloading machines (Hoskin & Bownes 2006: 209). 
The change from low and medium dose-rate systems delivering a 
radiation dose at dose rates of around 1 to 1.5 Gy/h to HDR systems 
delivering doses at a dose-rate similar to a modern linear accelerator, 
around 1 Gy/min, has resulted in important changes in the way in which 
brachytherapy is used (Hoskin & Bownes 2006: 209). 
 
Until recently, brachytherapy planning and dosimetry was based on fixed 
rules and fixed source geometries to achieve dose homogeneity within a 
planned volume. This was often based on the traditional schools of 
Manchester dosimetry and the Paris rules for interstitial therapy, which 
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had served well for many years (Hoskin & Bownes 2006: 2100). Often, 
however, they could not be fulfilled completely and even the most 
experienced brachytherapist will not always achieve a perfect implant with 
consequent adverse effects on dosimetry. The basis of gynaecological 
brachytherapy has for many years been the use of point A prescription 
points and organ-at-risk dosimetry limited to the ICRU rectal and bladder 
point estimates. Although a pragmatic approach, this is now seen to be 
anachronistic in the modern era of three-dimensional imaging. The 
conventions of EBRT, that define clinical target volumes and the organs at 
risk, and plan the target volumes, are slowly being embraced by 
brachytherapy  (Hoskin & Bownes 2006: 210). 
 
As fixed rules have been replaced by cross-sectional and three-
dimensional planning, software systems and algorithms have become 
increasingly sophisticated. Computer-assisted dose calculations around a 
brachytherapy implant are generally now based on the American 
Association of Physicists in Medicine Task Group 43 formalism. Another 
recent technological advance is the development of three-dimensional 
image-based treatment planning systems. The more advanced systems 
on the market allow full image-based manipulation, contouring tools, and 
automated catheter reconstruction. Three-dimensional imaging using 
computed tomography (CT) scans, magnetic resonance imaging (MRI), 
ultrasound, or a combination of 2 modalities through image fusion has 
allowed for accurate target and critical organ delineation and improved 
applicator or source localisation (Hoskin & Bownes 2006: 210). 
 
 
2.11 Conclusion 
The literature review supports the use of HDR-ICBT in combination with 
EBRT as a curative modality in the management of uterine cervical 
cancer. The potential late toxicity of large doses per fraction can be 
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overcome through adequate fractionation. Studies have shown a reduction 
in the doses to sensitive structures such as the rectum and bladder make 
the probability of late complications with HDR brachytherapy comparable 
to that of LDR brachytherapy. A study done by Ferrigno et al. (2005), 
however, reported that fewer late rectal complications were observed in 
the HDR brachytherapy group than in the LDR brachytherapy group. 
These findings were probably the result of the relatively low HDR 
brachytherapy dose delivered to point A (Ferrigno et al. 2005: 1108). 
Analysis of world-wide reviews (retrospective studies as well as 
prospective randomised clinical trials) suggests that LDR and HDR 
treatments are probably equivalent in terms of survival, local control and 
morbidity. The methodology of the retrospective study used in treating 
uterine cervical cancer patients at the Department of Oncotherapy, 
Bloemfontein is discussed in Chapter 3. 
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CHAPTER  3 
METHODOLOGY 
 
 
3.1 Introduction 
This is a retrospective study and a quantitative analysis of data captured 
by means of a data source form of patients treated at the Department of 
Oncothererapy, Bloemfontein for FIGO stages I-III uterine cervical cancer 
from January 1998 to December 2003. The methodology described in this 
chapter involves patient inclusion, the research tool that was designed and 
utilised, the calculations of the BED to the tumour and the rectum, the 
retrospective scoring of the late radiation complications and the statistical 
analysis of the retrospective study. The context of EBRT, HDR-ICBT and 
treatment planning describes the generic treatment procedure that was 
followed for each patient in the study. The sequence of events is 
described to illustrate the background to the methodology of this study.  
 
 
3.2 Research design 
This research design is a formal study which involves precise procedures 
and data source specifications, but it also has an element of exploration in 
calculating the biologically effective doses for the treatment schedule. The 
study was based on an ex post facto design, which means that the 
researcher can only report on the results of the analysis of those data 
which were captured by the radiation oncologists, medical physicists and 
radiation therapists during patients` radiotherapy treatment. Analytically, 
the study has a longitudinal design, given that the efficiency is analysed 
for specific years, as well as over a period of time (Cooper & Schindler 
2005: 146-149). It is a statistical study that will generate results that can 
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be incorporated into the current treatment schedule (EBRT & HDR-ICBT) 
for cervical cancer patients.  
 
 
3.3      Patient selection 
A list of patients that were treated with EBRT and HDR-ICBT for cervical 
carcinoma (FIGO stages I-III) was obtained from the HDR-ICBT statistics 
book at the Department of Oncotherapy, Bloemfontein. Between January 
1998 and December 2003, 696 patients with histologically proven 
carcinoma of the cervix were treated with curative intent at the Department 
of Oncotherapy, Bloemfontein. These patients` files were analysed to 
select the patients who would fit the inclusion criteria for the study. Tables 
3.1 & 3.2 show the criteria used for patient inclusion and exclusion. 
 
Table 3.1 Criteria for patient inclusion  
 1.   Patients treated at the Department of Oncotherapy, Universitas 
Annex, Bloemfontein, for cancer of the cervix. 
  
2.     Patients who received only radiotherapy (EBRT & HDR-ICBT) as 
        treatment modality. 
3.    Patients with FIGO stages I-III. 
4.     Patients with a minimum of a two year follow-up record for 
        analysis of late radiation complications. 
 
 
 
Table 3.2 Patient exclusion details 
1.   Patients with no positive histology and/or uncertainty about the 
      treatment received. 
 
2.   Patients not treated in Bloemfontein and whose treatment 
      details were unavailable, incomplete or impossible to interpret. 
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Table 3.2  continues 
3.   Patients who had a hysterectomy before radiotherapy. 
 
4.  Patients who were treated from 2002 with radiotherapy and    
     chemotherapy or were part of clinical trials. 
 
5.   Patients without a two-year follow-up examination. 
6.   Patients who had their follow-up examinations in other provinces 
      e.g. Northern Cape & Lesotho. 
 
7.   Patients whose EBRT- CT plans were not stored on CD records/ 
      tapes.  
 
8.   Patients who received no therapy at all, because they stayed 
      away or because of the advanced stage of the disease. 
 
9.   Patients excluded for non-medical reasons, refused treatment, or 
      did not complete radiotherapy because they disappeared and 
      could not be traced. 
 
 
After applying the exclusion criteria, the initial 696 patients of the study 
were reduced to a sample of 94 patients (See the reasons in Table 4.2). 
 
 
3.4 External beam radiotherapy  
The technique used was by four-field-box with anterior, posterior and two 
lateral planned fields with classic limits. The field extended superiorly to 
the L5-S1 interspace level and inferiorly to the obturator foramen. 
Laterally, the field extended 1cm beyond the bony margin of the pelvis at 
its widest point. The anterior and posterior borders of the radiation field is 
the plane of the anterior third of the symphisis pubis and the junction of 
S2/3, respectively. The radiation field size was determined and verified 
with simulation (AP-and LAT radiographs) and the patients were taken for 
computerised tomography. In patients treated with EBRT the dosimetry of 
the box field was calculated using computer-based software. 
Computerised isocentric planning was done on the CADPLAN Treatment 
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Planning System by using the computerised images of the patient`s pelvis 
so as to determine the planned-tumour-volume (PTV) for treatment Figure 
3.1.  
  
 
               Figure 3.1       The “four field box” technique (Permission to use 
                                       above figure has been duly granted.)  
 
The relative doses given by EBRT vs. brachytherapy depend upon the 
initial volume of disease, the ability to displace the rectum, the degree of 
tumour regression during pelvic irradiation and institutional preference 
(Nag et al. 2000: 202). The standard prescribed treatment for EBRT at the  
Department of Oncotherapy, Bloemfontein, is shown in Table 3.3 
 
Table 3.3 Treatment protocol for EBRT at the Oncotherapy 
                Department, Bloemfontein (n=94) 
EBRT-Dose per 
fraction 
EBRT-no. of 
fractions 
Total dose of EBRT  
2 Gy/fr. 25 fr. 50 Gy 
Abbreviation: fr = fraction 
 
All the patients were treated with a dose of 50 Gy in 25 daily fractions of 2 
Gy/fraction in 6 weeks. The total treatment duration was kept to less than 
eight weeks, because prolongation of total treatment duration can 
adversely affect local control and survival (Nag et al. 2000: 202). The 
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overall treatment duration would be unduly prolonged if the HDR-ICBT 
was started only after completion of EBRT, because multiple insertions 
are required for HDR-ICBT. Therefore, it was necessary to interdigitate the 
implants during EBRT (but EBRT was not given on the day of HDR-ICBT). 
Typically, if the vaginal geometry was optimal after two weeks of EBRT, 
HDR-ICBT was commenced once weekly.  
 
 
3.5 High dose-rate – Intracavitary brachytherapy 
All 94 patients were evaluated after the second week of pelvic EBRT 
regarding the anatomic and geometrical conditions of the cervix for HDR-
ICBT treatment. If it was optimal, the patient could start with HDR-ICBT. A 
Nucletron Microselectron device delivering HDR-ICBT was used with an 
Ir192 source with a nominal activity of 10 Ci. 
 
3.5.1 Insertion technique 
Ideally the applicator insertion, simulation and treatment should take place 
in a dedicated brachytherapy suit to avoid unnecessary patient movement 
(Nag et al. 2000: 203). However, because of financial implications and the 
structural layout of the Department of Oncotheapy, Universitas Annex, the 
best option was to transfer patients from the simulator to the HDR-ICBT 
treatment room via a trolley. Every effort was made to minimise patient 
and applicator movement so that the dosimetry performed on treatment-
planning radiographs matched patient and applicator position during 
treatment.  
 
The insertion of the ring applicator was done at the simulator by an 
oncologist, assisted by a professional nurse and is the treatment 
procedure followed by the Department of Oncotherapy, Universitas Annex 
(and for this study). The patients were positioned in a supine position on 
the simulator-table on top of a pat slide. A pat slide (Figure 3.2) is an 
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apparatus used to assist in moving the patients from the simulator bed to 
a trolley, with minimum patient and applicator movement. Every attempt 
was made to minimise patient movement when transferring them to the 
treatment room. 
 
     Figure 3.2      “ Patslide “– Patient transfer apparatus 
 
Conscious sedation was administered to the patients by the oncologist, 
whereafter the patients were positioned in the lithotomy position. Patient 
discomfort can lead to suboptimal packing and the inability to place the 
optimal applicator size, therefore conscious sedation was used for HDR-
ICBT whenever possible and was administered by individuals who were 
properly trained and familiar with this approach.  If the applicator position 
is not optimal, it can be very difficult to make applicator adjustments when 
the patient is not sedated and cannot be positioned in stirrups. 
 
It was important to choose an applicator that could optimally treat the 
disease and could be placed in an anatomically distorted vagina. The 
applicator used for HDR-ICBT consisted of the ring applicator, which is 
available in two different angles, 60o (Figure 3.3) and 450 sets. Each ring 
applicator set consists of three components, inserted separately, and 
attached via connecting screws. The central applicators used are available 
in different lengths (2, 4 and 6 cm) and the ring applicators come in 
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different ring sizes (2.4, 3 and 3.4 cm) with plastic caps. It was important 
that the plastic caps of the ring applicator were in place with each 
insertion, because excessive vaginal mucosal doses would be delivered 
without them. Displacement of the rectum away from the applicator by 
means of an in-built rectal retractor prevented high doses being delivered 
to the rectum and thus minimised late complications to the rectum.  
 
The applicator size for each insertion was determined by the vaginal 
geometry and tumour shrinkage of each patient. The applicator positioning 
and packing would be adjusted from fraction to fraction if there were any 
deficiencies in the initial insertions. Optimum applicator placement was 
critical in maximising local control and minimising complications. The ring 
applicator had to be positioned by the oncologist at the cervical os of each 
patient, because HDR-ICBT treatment planning was done to point A which 
is 2 cm lateral and 2 cm superior from the cervical os of each patient. The 
ring applicator was particularly useful when the vaginal fornices were 
asymmetric or absent and was easy to use because it has a reproducible 
geometry and was easy to insert.  
 
A Foley`s catheter was inserted into the rectum and 20-40 ml of contrast 
medium (Barium) was slowly instilled into the rectum to demonstrate the 
anterior wall up to the rectosigmoid junction before radiographs were 
obtained. The patients were then positioned in the supine extended 
position in which the radiographs were taken. To avoid any discrepancy in 
normal tissue doses between patient positions, it was important to treat 
the patients in the same position as that in the localisation radiographs. 
The applicator device was fixed to the patient and the patslide via masking 
tape.  
 
Anterior- (AP) and lateral (LAT) radiographs (Figures 3.3 & 3.4) were 
taken at the simulator with the patient in the supine extended position for 
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receiving HDR-ICBT. Good quality radiographs had to be obtained for 
treatment planning and dosimetry with each fraction. The position of the 
contrast outlined rectum was drawn in by the oncologist on the lateral 
radiograph, after which the patients were transferred from the simulator 
bed to a trolley and taken to the nearby HDR-ICBT treatment room where 
the Ir-192 Nucletron Microselectron afterloading system (nominal activity 
of 10 Ci) was connected to the applicators. 
 
 
 
 
 
 
 
            
           
   
          Figure 3.3 AP-radiograph                Figure 3.4 LAT-radiograph 
 
3.5.2 Treatment planning  
HDR-ICBT treatment planning was done by a medical physicist at the 
Department of Oncotherapy, Universitas Annex, using the computerised 
planning program PLATO SYSTEM 3.3.1, version 2, developed by 
Nucletron International BV, The Netherlands. The standard prescribed 
protocol of 2 Gy/treatment to the highest rectum dose point was 
prescribed by the oncologist. These rectum dose points were thus defined 
on the lateral radiograph and translated to the treatment planning system. 
The dose to point A was then normalised to the highest rectum dose point. 
Point A was defined on the radiographs as being 2 cm superior (along the 
central applicator) to the flange abutting external cervical os and 2 cm 
lateral from the axis of the central applicator (Figure  3.5). 
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Figure 3.5     Point “A “ 
 
The dose to point A differed for each patient due to different rectum 
positions during each HDR-ICBT treatment. Thus the dose to clinical 
points A would vary as a function of the highest rectum dose point for 
each fraction given. Figure 3.6 demonstrates the change in rectum 
positions for each fraction given.   
 
 
 
 
 
 
 
 
 
 
     
           Figure 3.6      Different rectum positions drawn in by  
                                  the Oncologist  for every fraction given   
 
A A
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The dose prescription for HDR-ICBT treatment protocol for all 94 patients 
is shown in Table 3.4. The total dose to point A was obtained by addition 
of the recorded doses to point A for each fraction given. A minimum  total 
dose of 15Gy to point A was achieved through multiple HDR-ICBT 
fractions (4-6). 
 
        Table 3.4 Treatment protocol for HDR-ICBT at the Oncotherapy 
                         Department, Bloemfontein (n=94). 
Dose per fraction Number of 
fractions 
Total dose to point A 
2 Gy (2Gy/fr. normalised 
to the highest rectum 
dose point) 
4-6 fr. Cumulative recorded dose to 
point A (min. of 15 Gy) 
Abbreviations: fr = fraction: GTV = gross tumour volume 
 
Dosimetric planning of HDR-ICBT was performed in each application for 
all patients by a standard plan template, which is based on the definition of 
the Manchester System of point A. Standard plans were developed for 
each of the ring applicator sets (450 or 600 degree sets) in use, and source 
dwell times and positions were adjusted to suit the dose distribution 
required for each individual patient.  
 
The position of the rectum relative to the ring applicator was defined on 
the lateral radiograph by the oncologist at the Department of Oncotherapy, 
Universitas Annex, and the dose distribution, calculated by the medical 
physicist for each individual patient, was normalised with respect to the 
maximum rectal dose. The rectal reference point according to the 
guidelines in the ICRU Report 38 (1985) was therefore not used. The 
lateral X-ray film, which verified the placement of the ring applicator in 
regard to the barium-outlined rectum, was used by the physicist to portray 
the rectum dose points in a 2D-projection, with the applicator shapes used 
in the standard plan templates to perform the dosimetric plan. Pear- 
shaped distributions were required, therefore manual optimisation was 
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done. No planned optimisation was thus done and the prescribed dose 
was computed to point A. However, in some cases the dwell positions 
were altered from the standard plan template because of a dose 
escalation to the rectum caused by its position in regard to the central 
applicator.  Figure 3.7 shows the standard calculated isodose distribution. 
  
 
Figure 3.7  Isodose curves generated with fixed relative dwell  
                   weighting based on the Manchester System  
                   (Permission to use above figure has been duly granted.) 
 
 
3.6      Calculations 
The dose effectiveness of the fractionation schedule was analysed 
retrospectively by calculating the cumulative biologically effective dose 
(BED) of the combination of EBRT and HDR-ICBT for FIGO stages I-III 
cervical cancer patients.  
 
Calculations of the biologically effective dose of the fractionation schedule 
were done by the Department of Biostatistics. On the basis of the LQ 
model, the cumulative biologic effective dose (BED) to the tumour and the 
rectum, generated from the contribution of EBRT and HDR-ICBT, was 
calculated for all patients. The biological effective dose was calculated to 
the tumour (/ = 10) and the rectum (/ = 3) for both EBRT and HDR-
ICBT. The cumulative BED to the tumour  for each patient  was the sum of 
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the total EBRT midline dose (50 Gy) and the total point A dose of HDR-
ICBT. The cumulative BED to the rectum for each patient was the sum of 
the EBRT dose, determined by dose-volume-hystograms (DVH), and a 
dose of 2 Gy/fraction prescribed to the highest rectum dose point for HDR-
ICBT. The cumulative BED for the tumour (Gy10) and the rectum (Gy3) 
were calculated by using equation 2 (See Chapter two – Time-dose 
models).   
 
 
3.7 Research tool 
A patient data source form was designed as a research tool to retrieve the 
relevant data for this study from the patients` radiotherapy treatment files 
and their follow-up notes (Appendix IA). All the necessary information was 
categorised under specific headings, making it easier to retrieve the 
relevant data for statistical analysis. 
 
The data source form contained the patients` demographics; pre-
treatment details such as FIGO staging; radiotherapy and brachytherapy 
details; the tumour and rectum doses; calculated BED values for EBRT 
and HDR-ICB. The follow-up details included the following: tumour 
recurrence and control, treatment received, scoring of late radiation 
complications according to the RTOG/EORTC scoring criteria; metastases 
and survival. Survival was measured from the first day of radiotherapy 
treatment to the last follow-up date/death. 
 
A pilot study, using the designed data source form as research tool, was 
conducted on twenty patients` radiotherapy treatment files and follow-up 
notes to see if the data source form would be effective in retrieving the 
relevant information needed for analysis. The original data source form 
was altered after the pilot study was conducted. The FIGO stages of the 
patients were adjusted to accommodate all stages of the 94 patients 
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included in the study. Second and third late radiation complications were 
also added to the data source form. The data source form was proof-read 
by a statistician and an oncologist and no alterations were required. 
 
 
3.8 Scoring criteria for late radiation complications 
The retrospective scoring of the late radiation complications was done by 
the researcher using the information notes captured by the radiation 
oncologists during the patients` follow-up examinations. Late radiation 
complications were scored according to the RTOG/EORTC – late radiation 
morbidity scoring scheme (Cox et al. 1995). The criteria for scoring the 
late complications of the patients are summarised in Table 2.2. 
 
 
3.9      Statistical analysis and follow-up 
Statistics have a contribution to make in all phases of a research project 
from the planning, through the data analysis, the interpretation and 
discussion of the results, to their publication (Katzenellenbogen, Joubert & 
Abdool Karim 1999: 101). The researcher consulted a statistician to 
discuss the statistical aspects of the research project in the planning 
phase, as well as the analysis and writing phase of the thesis. 
 
Results were summarised by frequencies and percentages (categorial 
variables) and means, standard deviations, median, minima and maxima 
(numerical variables). The software used was SAS 9.1.3 Service Pack 3. 
Survival analysis was used to determine the probability of recurrence, late 
complications and metastases at various time points. The cumulative BED 
values of the combination of EBRT and HDR-ICBT were investigated 
using the log-rank test based on survival analysis. The data collected for 
this retrospective study was processed by the Department of Biostatistics, 
University of the Free State, Bloemfontein. 
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The patients were followed-up by radiation oncologists by means of a 
clinical examination one month after radiotherapy had been completed. 
After that the patients were followed-up every three months for the first 
year and every four months for the second and third year. Follow-up 
procedures included a clinical (pelvic) examination and cervical 
Papanicolaou smears. When central and/or parametrial recurrence was 
suspected by pelvic examination and/or Papanicolaou smears, a biopsy 
was taken for confirmation. A chest radiograph was taken annually. Other 
imaging studies such as computer tomography, ultrasonography and bone 
scintigraphy were not routinely performed. 
 
 
3.9 Conclusion 
Although HDR brachytherapy for cervical cancer has been implemented 
for more than 30 years, there are still controversies regarding its efficacy 
and long-term side effects. Each institution should follow a consistent 
treatment policy, including complete documentation of treatment 
parameters and correlation with clinical outcome (pelvic tumour control, 
survival and complications) (Nag et al. 2000: 202). Chapter 4 shows the 
results obtained for this retrospective study using the fractionation 
schedule of EBRT and HDR-ICBT in treating patients with uterine cervical 
cancer at the Department of Oncotherapy, Bloemfontein. 
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    CHAPTER  4 
RESULTS
 
 
4.1 Introduction 
This is a retrospective analysis of the dose effectiveness and the 
incidence of late radiation complications in the radical treatment of 
patients diagnosed with uterine cervical cancer. The objectives of the 
study were to calculate the BED values to the tumour and the rectum and 
to score the incidence of late radiation complications according to the 
RTOG/EORTC scoring criteria. These results, as well as other information 
gathered by the data source form regarding patient selection, patient 
demographics, tumour characteristics, tumour control, metastases and 
survival are reflected in this chapter. The layout of the results follows that 
of the data source form. 
 
 
4.2 Patient selection 
From January 1998 to December 2003, 696 patients diagnosed with FIGO 
stages I-III cervical cancer completed their radiotherapy treatment (EBRT 
and HDR-ICBT) at the Department of Oncotherapy, Bloemfontein. The 
treatment and follow-up details of these patients were analysed to select 
only those who would fit the patient selection criteria for this retrospective 
study (chapter 3). Table 4.1 shows the number of files with complete 
treatment and follow-up details which could be used for the study. 
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 Table 4.1 Patient treatment files suitable for study 
Year 
Patients 
treated 
Files of 
patients not 
suitable Files of patients suitable 
1998 70 62 8 
1999 115 100 15 
2000 157 147 10 
2001 114 93 21 
2002 100 88 12 
2003 140 112 28 
Total 696 602 94 
  
From the information in the 696 patients` files which were analysed, 348 
patients did not have their follow-up examinations in the Free State, 196 
had follow-up periods of less than two years and 58 patients did not have 
complete dosimetric data. Therefore, 94 patients who had complete 
treatment and follow-up documentation and a minimal follow-up period of 
two years were included in the current study. The reasons for patient 
exclusion are shown in Table 4.2. 
 
Table 4.2 Reasons for patient exclusion 
 
Number of Patients Reasons for exclusion 
196 Follow-up < 2 years 
348 Follow-up at other clinics in other provinces 
(Lesotho/Kimberley) 
58 Incomplete dosimetric data 
 
 
4.3 Patient demographics 
The mean age of the 94 patients was 55 years (Std Dev. 9.5), the 
youngest patient being 26 years and the oldest 76 years of age. Table 4.3 
illustrates the race groups involved of the 94 patients treated for uterine 
cervical cancer. The black population group dominated with 93 patients 
(98.94%). 
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           Table 4.3      Summary of race groups treated (n=94) 
  
 
 
 
 
All 94 patients were tested for HIV/AIDS, of whom 87 (92.55%) were HIV-
negative, while 7 (7.45%) patients were HIV-positive (Figure 4.1). Only 
one of the seven HIV-positive patients developed tumour recurrence 
(CD4-count = 480), while the remaining 6 patients had no tumour 
recurrence. The 7 patients who were HIV-positive had a median CD4-
count of 398.5 (range: 60-720).       
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 Figure 4.1      HIV/AIDS status of patients (n=94) 
 
 
4.4 Tumor characteristics 
All patients were staged according to the FIGO staging for uterine cervical 
cancer. The histology of cervical cancer is shown in Figure 4.2. Squamous 
carcinoma was dominant in 87 (92.55%) of the patients treated.  
Race Number of patients Percent 
Black 93 98.94 
Coloured 1 1.06 
Total 94  
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  Figure 4.2      Histology of uterine cervical cancer (n=94) 
 
Thirty-nine of the 94 cervical cancers were poorly differentiated, 33  
moderately differentiated, 8 well differentiated and in 12 patients the 
tumour differentiation was not stated (Figure 4.3). 
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            Figure 4.3      Differentiation of uterine cervical cancer cells    
                                   (n=94)                  
 
The cervical carcinoma was also analysed according to the endophytic or 
exophytic appearances. Exophytic type of tumours were dominant in 52 
patients and in 12 patients the tumour type was not stated (Figure 4.4). 
     
 62 
TUMOR TYPE
31.91
55.32
12.77
0
10
20
30
40
50
60
Endophytic Exophytic Not stated
%
 
 Figure 4.4     Endophytic/exophytic type of tumours (n=94) 
 
 
          The FIGO staging for the 94 cervical cancer patients is illustrated in Figure 
4.5. Of the 94 patients, 43  were stage IIIb1, 27 stage IIb2, 12 stage IIb1 
and only 1 patient was stage Ib. Clinically stage distribution of patients 
according to the FIGO criteria was as follows: Ib - 1 (1.05%),  IbI - 2 
(2.13%), IIb - 3 (3.19%), IIbI - 12(12.77%), IIb2 - 27 (28.72%), IIIbI - 43 
(45.74%) and IIIb2 - 6 (6.38%). 
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             Figure 4.5      FIGO staging of uterine cervical cancer 
                                    patients (n=94) 
 
 
The cumulative BED values for EBRT and HDR-ICBT for all  FIGO stages 
I-III cervical cancer patients is shown in Table 4.4. The majority of the 
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patients had a FIGO IIIb1 staging with a median cumulative dose of 86.01 
Gy10 to the tumour and a median cumulative dose of 105.43 Gy3 to the 
rectum.  
 
           Table 4.4    FIGO staging vs. cumulative BED values to the tumour  
           and the rectum  (n=94) 
                    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.5 Radiation therapy treatment 
Radiation therapy consisted of a combination of EBRT and HDR-ICBT.    
The EBRT was given over a six week period and the 4-6 fractions of HDR-
ICBT were interdigitated (once weekly) into the EBRT treatment schedule. 
The overall duration of treatment ranged from 32 to 60 days (mean, 41 
days). The energy chosen to treat the patients for EBRT depended on the 
pelvic separation of the patients (larger patients-higher energy). Figure 4.6 
illustrates that most of the patients (56) received their EBRT treatment via 
the 6-MV photon beam accelerator (ELEKTA SL 75/6).  
 
FIGO 
stage Observations 
Cummulative 
TUMOR 
BED10 Cummulative Rectal BED3 
  Median Median 
Ib 1 88.5965 113.6959 
Ib1 2 85.4123 107.4882 
IIb 3 92.0848 109.0957 
IIb1 12 89.1473 108.2454 
IIb2 27 89.0645 105.6285 
IIIb1 43 86.0190 105.4339 
IIIb2 6 86.7146 105.5069 
TOTAL 94 
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             Figure 4.6      Energy chosen for EBRT treatment (n=94) 
  
Patients received 4-6 fractions of HDR brachytherapy to obtain a minimum 
dose of 15 Gy to point A. Table 4.5 shows that (of the 94 patients) 70 
patients had received 4 fractions of HDR-ICBT to attain a minimum total 
dose of 15 Gy to point A, with only one patient receiving six fractions of 
HDR-ICBT treatment. The point A dose differs for each fraction given, 
because of the change in the rectum position for each HDR-ICBT 
treatment. 
   
Table 4.5    Number of fractions received for HDR-ICBT  (n=94)                     
Number of HDR 
fractions 
Number of 
patients 
Percent 
4 70 74.19 
5 23 24.73 
6 1 1.08 
Total 94  
 
The standard prescribed dose for each HDR-ICBT treatment was 2 
Gy/fraction, normalised to the highest rectum dose point. Therefore the 
dose to point A varied between fractions, because the position of the 
rectum was different with every fraction given. The position of the rectum 
was determined on the lateral control films for each HDR brachytherapy 
treatment administered. The median dose to point A for the 94 patients 
was 3.66 Gy (Std Dev 1.03) ranging from 2.55 Gy – 6.68 Gy (given in 4-6 
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fractions). The cumulative recorded mean dose at point A for the 94 
patients who received HDR-ICBT treatment, was 17.96 Gy. 
 
 
4.6 Biologically effective doses (BED)  
The linear quadratic model was used to calculate the BED for the 
fractionation schedule used in treating the uterine cervical cancer patients 
of the study. 
 
4.6.1  BED values of EBRT 
The BED values for the tumour (Gy10) and the rectum (Gy3) for EBRT are 
shown in Table 4.6. Both these values were used to calculate the 
cumulative BED for the combination of EBRT and HDR-ICBT. 
 
 
Table 4.6      EBRT- BED values to the tumour Gy10 and the 
                     rectum Gy3 (n=94) 
 TUMOR Gy10 RECTUM Gy3 
Mean BED 66.5 92.01 
Standard deviation 1.15 3.07 
Median BED 66.38 92.19 
Minimum BED 63.45 79.12 
Maximum BED 69.05 97.30 
  
 
4.6.2  BED values of HDR-ICBT 
The BED values for the tumour (Gy10) and the rectum (Gy3)  for HDR-
ICBT are shown in Table 4.7. These values were used to calculate the 
cumulative BED for the combination of EBRT and HDR-ICBT. 
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Table 4.7    HDR-ICBT-BED values to the tumour Gy10 and the 
                   rectum Gy3 (n=94)                
 TUMOR Gy10 RECTUM Gy3 
Mean BED 21.09 14.18 
Standard deviation 4.31 1.62 
Median BED 20.33 13.33 
Minimum BED 4.15 10.00 
Maximum BED 34.30 20.00 
 
 
 
4.6.3 The cumulative BED values of EBRT and HDR-ICBT 
Calculations were made using the LQ model to determine the cumulative 
BED values for the tumour (Gy10) and the rectum (Gy3)   respectively. The 
cumulative tumour BED of EBRT & HDR-ICBT had a median value of 
87.27 Gy10 and the cumulative rectum BED of EBRT + HDR-ICBT had a 
median value of 106.26 Gy3 (Table 4.8). 
 
Table 4.8   Cumulative BED values for EBRT & HDR-ICBT(n=94) 
 TUMOUR Gy10 RECTUM Gy3 
Mean BED 87.59 106.20 
Standard deviation 4.36 3.55 
Median BED 87.27 106.26 
Minimum BED 72.98 93.71 
Maximum BED 101.18 113.86 
 
 
4.7      Follow-up results 
The median follow-up time for all 94 patients was 40 months (3.3 years), 
(range: 20-93 months). 
  
             4.7.1   Tumour recurrence 
Eleven (11.7%) of the 94 patients had tumour recurrence, while 83 
patients (88.3%) had no tumour recurrence (Figure 4.7).  
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              Figure 4.7     Tumour recurrence of uterine cervical cancer  
                                   patients (n=94) 
  
        
The histology results of the 94 uterine cervical cancer patients showed 
that three of the seven patients (42.9%) with adenocarcinoma had tumour 
recurrence, while eight of the eighty-seven patients with squamous 
carcinoma (9.2%) presented with tumour recurrence. Between the two 
types of tumours, patients with adenocarcinoma have a significantly 
greater chance of developing tumour recurrence than patients diagnosed 
with squamous carcinoma (p=0.03). Only one of the 11 patients who 
developed tumour recurrence was HIV-Positive (CD4-count=480). 
            The probability of tumour recurrence at various time points (using survival 
           analysis) is shown in Table 4.9.   
   
 
 Table 4.9      Probability of  tumour recurrence (n=94) 
TIME SPAN PROBABILITY 
6 months 0.01 
1 year 0.03 
2 years 0.09 
3 years 0.09 
4 years 0.13 
 
 
 68 
Of the 11 patients with tumoUr recurrence (FIGO stages IIb2-IIIb2), five 
patients had stage IIIb1 and four patients had stage IIb2 cervical cancer 
(Table 4.10). 
           
          Table 4.10    FIGO staging of patients  with tumour  
                    recurrence (n=11) 
FIGO STAGE Number of patients Percent 
Stage IIb2 4 36.36 
Stage IIIb1 5 45.45 
Stage IIIb2 2 18.19 
Total 11  
 
          Of the 11 patients with tumour recurrence, 6 patients had local infiltration, 
while the remaining 5 patients showed none (Table 4.11).  
 
           Table 4.11  Summary of local infiltration (n=11) 
Local infiltration 
Number of 
patients Percent 
Yes 6 54.55 
No  5 45.45 
Total 11 
 
   
Figure 4.8 shows that of the six patients with local infiltration, five had 
bladder infiltration and only one had rectum infiltration.  
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            Figure 4.8   Organs  infiltrated (n=6) 
 
 69 
The 11 patients with tumour recurrence were treated with either one or 
with a combination of modalities. Nine of the patients received 
chemotherapy, eight patients received supportive care and two  patients 
received HDR-ICBT (Figure 4.9).  
TREATMENT OF PATIENTS WITH 
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 Figure 4.9 Treatment of patients with tumour recurrence (n=11)                             
 
  
The cumulative BED values for EBRT and HDR-ICBT for the patients with 
or without tumour recurrence is shown in Table 4.12. The cumulative 
median BED10 for the 11 patients with tumour recurrence was 86.02 Gy10 
and 87.62 Gy10 for the 83 patients who did not have tumour recurrence. 
These cumulative median BED10 values did not differ statistically (p=0.68).  
 
Table 4.12     Tumour recurrence vs. BED10 (n=94) 
Tumour recurrence Frequency Cummulative tumour BED10 
  Median 
Yes 11 86.0251 
No 83 87.6183 
TOTAL 94  
 
 
 
4.7.2 Late radiation complications 
The incidence of late radiation complications was retrospectively analysed 
according to the RTOG/EORTC scoring criteria. Of the 94 patients in this 
study, 15 had RTOG/EORTC Grade 1-4 late rectal/bladder complications 
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(Table 4.13). These late radiation complications occurred at a median time 
interval of 12.36 months (range: 1-31 months) after completion of 
radiotherapy treatment.   
 
           Table 4.13    Incidence of late radiation complications  (n=94) 
LATE RADIATION 
COMPLICATION(S) 
Number of 
pateints Percent 
Yes 15 15.96 
No 79 84.04 
Total 94  
 
  
The FIGO staging of the 15 patients who presented with late radiation 
complications is illustrated in Table 4.14. Most patients were stages IIb2 
and IIIb1 uterine cervical cancer, respectively. 
 
Table 4.14   FIGO staging of patients with late radiation 
                     complications (n=15) 
        FIGO STAGE Number of patients Percent 
Stage IIb 1 6.67 
Stage IIb1 3 20 
Stage IIb2 4 26.66 
Stage IIIb1 6 40 
Stage IIIb2 1 6.67 
Total 15 1 
 
 
Of the 15 patients who presented with late radiation complications, 10 had 
late radiation complications of the bladder and 5 patients had rectum 
radiation complications (Table 4.15). Two of the 15 patients who 
presented with late radiation complications were HIV-positive (CD4-counts 
of 550 & 480, respectively). 
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Table 4.15 Site of late radiation complications (n=15)  
 
SITE OF RADIATION 
COMPLICATIONS Number of patients Percent 
Rectum 5 33.33 
Bladder 10 66.67 
Other 0 0 
Total 15  
 
 
Most of the patients with bladder complications presented with 
RTOG/EORTC grade I/II late radiation complications. The median time for 
the development of rectal complications was 6 months (range: 1-10 
months), whereas that for bladder complications was 17 months (range: 3-
31 months). Table 4.16 shows the crude incidence (grading) of first late 
radiation complications (RTOG/EORTC scoring of these organs). The late 
rectal complications varied from blood streaked stool and rectal bleeding 
to proctitis. Bladder complications were teleangiectasia, intermittent 
macroscopic haematuria and severe frequency and dysuria. 
 
Table 4.16 Crude incidence of first late radiation complications 
                      according to the RTOG/EORTC scoring (n=15) 
Site Grade I Grade II Grade III Grade IV GradeV 
Rectum 
(n=5) 
3 1 1 0 0 
Bladder 
(n=10) 
6 3 1 0 0 
 
 
These 15 patients received either one or a combination of treatments for 
the late radiation complications. Most of these patients received 
medication or hyperbaric oxygen (Figure 4.10). 
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TREATMENT FOR LATE RADIATION 
COMPLICATIONS
17.65
82.35
0.00 20.00 40.00 60.00 80.00 100.00
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%
 
 Figure 4.10    Treatment for patients with late radiation 
                        complications  (n=15) 
 
Three of the 15 patients with late radiation complications also presented 
with a second late radiation complication. These patients first presented 
with late radiation complications of the rectum, followed by second late 
radiation complications of the bladder(2) and rectum (1).  Table 4.17 
shows the RTOG/EORTC scoring of the second late radiation 
complication of these patients. Of the three patients who presented with a 
second late radiation complication, one patient presented with a grade II 
rectum complication (increase stool frequency and bleeding) and the other 
two  had  grade III bladder complications (severe frequency and dysuria). 
 
 
 
          Table 4.17  Crude incidence of second late radiation  
                             complications  according to RTOG/EORTC scoring (n=3) 
 
 
 
 
 
 
 
Site Grade 
I 
Grade 
II 
Grade 
III 
Grade 
IV 
Grade 
V 
Rectum (n=1) 0 1 0 0 0 
Bladder (n=2) 0 0 2 0 0 
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All of these patients were treated medically according to the 
symptoms.Only one of the three patients with a second late radiation 
complications developed a third, late radiation complication. The patient 
had a third, late radiation complication of the rectum (proctitis) and the 
bladder (cystitis). The patient received palliative treatment (medication). 
Table 4.18 shows the probability of late radiation complications at various 
time points (using survival analysis). 
 
           Table 4.18     Probability of late radiation complications  
                                  (n=94) 
TIME SPAN PROBABILITY 
6 months 0.05 
1 year 0.07 
2 years 0.11 
3 years 0.16 
4 years 0.19 
             
 
The cumulative rectum (BED3) values of EBRT and HDR-ICBT for the 
patients with or without late radiation complications is shown in Table 
4.19. The cumulative median BED for the rectum Gy3, of the 15 patients 
with late radiation complications was, 106.62 Gy3 and of the remaining 79 
patients, 105.89 Gy3. These doses also did not differ significantly (p=0.17). 
 
Table 4.19   Late radiation complications vs. BED3 (n=94) 
Late 
complications 
Number of 
patients 
Cummulative median 
rectum BED3 
Yes 15 106.6285 
No 79 105.8964 
TOTAL 94  
 
 
4.8 Metastases 
Of the 94 patients whose treatment details were analysed in this 
retrospective study, 7 patients (7.45%) developed metastases (Table 
4.20). Of these 7 patients, 6 also presented with tumour recurrence.  
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           Table 4.20   Patients with metastases at last follow-up  
                               (n=94) 
Metastases 
Number of 
patients Percent 
Yes 7 7.45 
No 87 92.55 
Total 94  
 
 
The areas where the cancer had spread to are illustrated in Figure 4.11. In 
some patients the cancer had spread to more than one site. The most 
common site was the para-aortic lymph nodes, followed by bone 
infiltration, lungs, liver and brain. These patients with metastases were 
treated with medication, radiation and/or chemotherapy.  
SITES OF METASTASES
18.18
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 Figure 4.11   Sites of metastases for patients with uterine  
                        cervical cancer (n=7) 
 
 
The probability of metastases at various time points (using survival 
analysis) is shown in Table 4.21. 
           Table 4.21 Probability of metastases (n=94) 
TIME SPAN PROBABILITY 
6 months 0 
1 year 0 
2 years 0.01 
3 years 0.01 
4 years 0.04 
5 years 0.09 
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4.9 Survival 
Among the 94 patients who were analysed in this retrospective study, the 
3.3-year cause specific survival was 100% for all FIGO stages I-III. 
 
4.10 Conclusion 
The results have shown the cumulative median BED10 values to the 
tumour and the BED3 values to the rectum of patients treated with a 
combination of EBRT and HDR-ICBT at the Department of Oncotherapy, 
Bloemfontein for the first time. Although the cumulative median BED10 
value of 87.27 Gy10 to the tumour could not be correlated to tumour 
recurrence of the patients, only 11.7% of the 94 patients treated presented 
with tumour recurrence. The median BED3 value of 106.26 Gy3  to the 
rectum could not be correlated to the incidence of late radiation 
complications, but only 15 of the 94 patients presented with late radiation 
complications. The results relevant to the objectives of this retrospective 
are discussed in chapter five. 
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CHAPTER  5 
 DISCUSSION  &  CONCLUSION 
 
 
 5.1 Introduction 
          This research study was undertaken to analyse retrospectively the dose 
effectiveness of the applicable fractionation schedule and the incidence of 
late radiation complications in the radical treatment of uterine cervical 
cancer. The dose effectiveness was analysed according to the calculated 
BED values obtained by using the LQ formula. The median BED values to 
the tumour (87.27 Gy10) and the rectum (106.26 Gy3) were then correlated 
to tumour control and incidence of late radiation complications. This 
chapter discusses the significance of the data source form as research 
tool, the advantages of implementing HDR-ICBT in combination with 
EBRT as treatment modality for uterine cervical cancer patients, the dose 
effectiveness and incidence of late radiation complications of the 
fractionation schedule used, as well as recommendations and 
shortcomings of the study. 
 
 
5.2 High dose-rate brachytherapy 
Use of HDR-ICBT in combination with EBRT in the treatment of uterine 
cervical cancer patients has increased worldwide, especially in developing 
countries, in many of which the incidence rates exceed 30/ 100 000 (Nag 
et al. 2002: 299). Considering the statistics of uterine cervical cancer 
patients treated at the Department of Oncotherapy, Bloemfontein 
(mentioned in Chapter One), the implementation of HDR-ICBT in 1994 
into the fractionation schedule was justified. The advantages of this 
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treatment modality in comparison to LDR brachytherapy include outpatient 
treatment, potential cost saving, shorter treatment time, elimination of 
personnel exposure, dose optimisation and maintenance of better 
applicator geometry, all of which make this procedure the treatment 
modality of choice (Nag 2004: 620). 
 
Recent studies published on HDR vs. LDR brachytherapy by Wong et al. 
(2003: 1254-1264), Ferrigno et al. (2005: 1108-1116) and Falkenberg et 
al. (2006: 49-55), have reported comparable results in terms of tumour 
control and toxicity using either LDR brachytherapy or HDR brachytherapy 
(HDRB). Falkenberg et al. (2006: 49-55), compared 103 LDR 
brachytherapy patients to 57 HDR brachytherapy patients and reported  
that for all uterine cervical cancer stages combined and stage for stage in 
both groups, there was no statistically significant difference in loco-
regional control, cause-specific survival and overall survival for LDR 
therapy compared with HDR therapy. Loco-regional control and overall 
survival were 78% and 60% for LDR compared to 76% and 55% for HDR 
at 3 years, respectively. The advantages of HDR-ICBT in comparison to 
LDR brachytherapy make it the definitive mode of treatment for uterine 
cervical cancer patients, with curative intent, at the Department of 
Oncotherapy, Bloemfontein. 
  
 
5.3      Dose effectiveness 
The main objective of this retrospective study was to analyse the dose 
effectiveness of the fractionation schedule implemented since 1994 at the 
Department of Oncotherapy, Bloemfontein, by calculating the biologically 
effective dose (BED) for the combination of EBRT and HDR-ICBT to the 
tumour Gy10 and the rectum Gy3, using the linear quadratic model. This 
was the appropriate model to use in the study, because it allowed 
distinction to be made between the fractionation and dose-rate 
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sensitivities of early and late responding tissues such as tumour tissue 
(early) and rectum (late). The results of this theoretical study were 
significantly dependent on the linear quadratic parameters used. The 
BED10 results obtained after analysis of the fractionation schedule for dose 
effectiveness at the Department of Oncotherapy, Bloemfontein, are 
summarised and compared to those of other fractionation schedules, 
Table 5.1. These results compare well with those of HDR brachytherapy 
fractionation schedules in recently published studies.   
 
           Table 5.1   BED10 values of the Department of Oncotherapy,   
                             Bloemfontein (1998-2003) and HDR fractionation  
                             schedules for recently published studies (Petereit &  
                             Fowler  2003: 1160). 
 Whole-
pelvis dose 
HDR FX BED Gy10  
Dept. of 
Oncotherapy,Bloemfontein 
(1998-2003). 
50 Gy 25 Fx Median of 
4 Gy x 4- 
6 Fx 
87 
Wong 40 Gy 20 Fx 7 Gy x 3 86 
 
 6 Gy x 4 88 
Sood 45 Gy 25 Fx 9 Gy x 2 89 
Ferrigno 45 Gy 25 Fx 6 Gy x 4 92 
Pearcey (NCIC trial) 45 Gy 25 Fx 8 Gy x 3 96 
GOG standard 45 Gy 25 Fx 6 Gy x 5 101 
ABS recommendations 
 
45 Gy 25 Fx 5.3-7.5 
Gy x 5-8 
Fx 
98-109 
Abbreviations: HDR = high-dose-rate; Fx = fractions; BED = biologically effective 
dose; NCIC =  National Cancer Institute of Canada; GOG = Gynecologic 
Oncology Group; ABS = American Brachytherapy Society. 
 
 
In a literature analysis of 24 articles on HDR brachytherapy fractionation 
schedules, publiched by Petereit and Pearcey (1999: 359-361), the 
median BED10 was 96 Gy10. The local control rate for uterine cervical 
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cancer stage Ib, IIb and IIIb disease was 91%, 82% and 71% respectively 
with a disease-free survival rate of 85%, 68% and 47% at 5 years 
respectively. No correlation was identified between point A BED and either 
survival or local control. 
 
Petereit et al. (1999: 1267-1274), reported on 173 uterine cervical cancer 
patients treated with 40-50 Gy of EBRT and five HDR-ICBT fractions of 
3.7-9.9 Gy each. The BED10 in their current schedule varied from 96 Gy10 
for nonbulky stage I/II disease to 109 Gy10 for stage IIIb. The 3-year local 
control and disease-free survival rate was 71% and 62% respectively. 
 
Sood et al. (2002: 1377-1387), reported on 49 uterine cervical cancer 
patients with cervical cancer treated with a combination of 45 Gy (1.8 
Gy/fr) of EBRT and 2 HDR-ICBT treatments of 9-9.5 Gy prescribed to 
point A. A BED10 > 89 Gy indicated a trend toward a better local control 
rate than patients who received < 89 Gy10. The 4-year control rate was 
83% and disease-free survival rate 70%. 
 
Toita et al. (2003: 1344-1353), reported on 88 uterine cervical cancer 
patients treated with 40 Gy of EBRT and 3 HDR-ICBT treatments of 18 Gy 
(point A dose of 6 Gy). The median cumulative biologically effective dose 
(BED) at point A (EBRT + ICBT) was 64.8 Gy10 for early disease and 76.8 
Gy10 for advanced disease. Their conclusion after analysing their 
fractionation schedule was that, in view of the therapeutic ratio, cumulative 
BED 70-80 Gy10 at point A was appropriate for uterine cervical cancer 
patients treated with a combination of EBRT and HDR-ICBT. 
 
The median BED10 for all 94 patients treated between 1998-2003 at the 
Department of Oncotherapy, Bloemfontein, was 87.27 Gy10 to the tumour. 
The median BED10 in the schedule varied from 88.85 Gy10 for nonbulky 
stage I/II disease to 86.36 Gy10 for stage IIIb patients. Although the BED10 
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value in this study was about 10-15 Gy10 less than the studies reported by 
Petereit & Pearcey (1999), Petereit et al. (1999), Sood et al. (2002) and 
Toita et a. (2003), the 3.3-year local control rate of 88.3% for all stages 
and a hundred percent overall survival compared well with these reported 
studies in the literature. Patients who developed local recurrence received 
a median of 86.02 Gy10, while those who did not developed tumour 
recurrence received a median of 87.62 Gy10. These BED10 values did not 
differ significantly (p=0.68). Thus BED10 values could not be correlated 
with local control. 
  
 The histology results of the 94 uterine cervical cancer patients showed 
that three of the seven patients (42.9%) with adenocarcinoma had tumour 
recurrence, while eight of the eighty-seven patients (9.2%) with squamous 
carcinoma presented with tumour recurrence.  Between the two types of 
tumours, patients with adenocarcinoma have a significantly greater 
chance of developing tumour recurrence than patients diagnosed with 
squamous carcinoma (p=0.03). The FIGO staging results of the eleven 
patients with tumour recurrence showed that two patients (18%) were 
stage IIIb2; four patients (36%) were stage IIb2 and five patients (45%) 
were stage IIIb1.  
 
 Although the patients of this study received EBRT & HDR-ICBT as 
treatment modality in a pre-chemotherapy era, the American 
Brachytherapy Society (ABS) recommends the addition of cis-platinum 
based chemotherapy during pelvic EBRT. Five prospective randomised 
trials have recently demonstrated a 10-15% increase in local control and 
survival without increase in complications when concurrent chemotherapy 
was added to radiation therapy. However, it is not advisable to administer 
chemotherapy concomitantly with brachytherapy, unless it is in the context 
of a controlled clinical trial. Increased complications have been reported 
with concomitant chemotherapy and brachytherapy (Nag et al. 2000: 203). 
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5.4 Late radiation complications 
Similarly, some studies have tried to establish a correlation between BED3 
and late rectal toxicity. Chen et al. (2000: 955-961) reviewed 128 patients 
with uterine cervical cancer. These patients were treated with 40-44 Gy of 
EBRT and 3-4 HDR-ICBT fractions of 5-7.2 Gy each. After 30-75 months 
of follow-up, 38 patients (29.7%) had late rectal complications. When 110 
Gy3 was used as the cutoff value, 19.6% (10 of 51) of patients whose 
cumulative BED3  was less than 110 Gy3 had rectal complications, while 
36.4% (28/77) of patients whose BED3 was greater than 110 Gy3 
developed rectal complications.  
 
The Brazilian Experience, as reported by Ferrigno et al. (2001: 1123-
1135), is one of the most concise HDR brachyhterapy papers written to 
date because the authors provided adequate fractionation details, 
calculated and correlated biologically effective doses to the tumour and 
late responding tissues and prospectively studied their patients. One-
hundred and thirty-eight patients were treated with 45 Gy EBRT and four 
HDR-ICBT treatments of 6 Gy prescribed to point A. Patients treated with 
cumulative BED at rectum points above 110 Gy3 had a higher but not 
statistically significant five-year actuarial rate of complications. Sood et al. 
(2002: 1377-1387) reported on 49 patients with cervical cancer treated 
with a combination of 45 Gy (1.8 Gy/fr) of EBRT and 2 HDR-ICBT 
treatments of 9-9.5 Gy prescribed to point A. The median BED3 at the 
rectal point in their study was 95.5 Gy3 (range 79.9-110.2). They 
suggested that the low rate of rectal complications in the study could be 
attributed to the low BED3 at the rectal point, although the point A doses 
were achieved as prescribed. 
 
Chung et al. (1996: 319) calculated both the maximal rectal dose to the 
anterior rectal mucosa identified by contrast medium and the ICRU report 
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38 (1985) reference rectal dose. They obtained a significant relationship 
between the occurrence of late rectal complications and both types of 
rectal doses. The maximal rectal dose estimated by contrast medium was 
greater and correlated better with late complications than did the strictly 
defined ICRU report 38 (1985) rectal dose.  
 
In the current retrospective study the fractionation schedule did not include 
the ICRU report 38 rectal reference point, but the maximal rectal dose to 
the anterior rectal mucosa identified by contrast medium. The standard 
prescribed protocol at the Department of Oncotherapy was 2 Gy/fraction, 
normalised to the highest rectum dose point to achieve a minimum total 
dose of 15 Gy to point A. The dose to point A therefore varied from patient 
to patient, and fraction to fraction. Point A is a geometric point in 
relationship to the cervical os and uterine axis and the rectal doses can be 
significantly different depending on the geometry of the implant, size of 
applicators, amount of packing, source of activity and optimisation with 
HDR-ICBT. The median dose per fraction to point A was 3.66 Gy/fraction 
and the total median dose to point A was 18 Gy. 
 
The median BED3 at the rectal point in this retrospective study was 106.2 
Gy3  (range 93.7 Gy-113.9 Gy). Patients who developed late radiation 
complications received a median of 106.62 Gy3, while those who did not 
develop complications received a median of 105.89 Gy3. These BED3 
values did not differ significantly (p=0.17), thus BED3 values could not be 
correlated with late radiation complications. The incidence and severity of 
late radiation complications was analysed and graded according to the 
RTOG/EORTC scoring scheme. Severe late rectal and bladder 
complications were uncommon in this retrospective study. One patient 
presented with Grade IV complications (proctitis and systitis). Ten of the 
fifteen patients with late radiation complications had late radiation 
complications of the bladder (grade I-III). This was expected, because the 
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HDR-ICBT treatment did not include bladder shielding. A study reported 
by Toita et al. (2003: 1344) suggest that cumulative BED3 at the rectal 
point should be kept below 100-120 Gy3 to prevent late rectal 
complication. At the Department of Oncotherapy, Bloemfontein the 
cumulative BED3 at the rectal point (106.2 Gy3 ) was within the above 
mentioned values and therefore only 16% of the 94 patients presented 
with late radiation complications. 
 
The incidence of late radiation complications occurred at a median time 
interval of 12.36 months (range: 1-31 months) after completion of 
radiotherapy treatment. Amongst the 15 patients who presented with late 
radiation complications (grade I-III), three had second late radiation 
complications (2 bladder- grade III and one rectum- grade II 
complications), and one of them had a third late radiation complication of 
the bladder and the rectum-grade IV.  
 
The probability of metastases at a five-year time point is 0.09, therefore 
making it negligible. Seven of the 94 uterine cervical cancer patients 
(7.45%) presented with metastases and of these seven, six presented with 
tumour recurrence. 
 
 
5.5      Recommendations 
The BED3 and BED10 values calculated for the fractionation schedule of 
this retrospective study at the Department of Oncotherapy, Bloemfontein, 
are adequate and the available data indicate that it is not necessary to 
adapt the prescribed treatment protocol for patients diagnosed with stages 
I-III uterine cervical cancer. 
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Regarding the RTOG/EORTC scoring of the late radiation complications, 
the researcher would suggest that these scoring sheets should be 
included in the patients` follow-up files and should be completed by the 
radiation oncologist after every follow-up examination for future research 
purposes on late radiation complications. 
 
All 94 patients of the retrospective study were tested for HIV/AIDS and the 
analyses showed that 7 patients (7%) were HIV-Positive. Only one of the 
11 patients who developed tumour recurrence was HIV-Positive (CD4-
count=480). The influence of the HIV status of patients on the dose 
effectiveness of a fractionation schedule could be an interesting research 
study for the future. 
 
The study had a three-year follow-up period, but according to Petereit et 
al. (2003: 1159-1161), longer follow-up results would be required to 
determine if lower BED10 values compromise pelvic control rates. The 
researcher would thus suggest looking at five-year follow-up results to 
determine whether or not BED10 values in this study compromise pelvic 
control rates.   
 
The current fractionation schedule places a lot of emphasis on the rectum 
dose, while the dose delivered to the bladder has been ignored. 
Considering that 10 of the 15 patients who presented with late radiation 
complications had bladder complications, it may be necessary for the 
future to take the total dose to the bladder of this schedule into account.  
  
 
5.6      Shortcomings of the study 
The original data source form was altered after the pilot study was 
conducted. The FIGO stages of the patients were adjusted to 
accommodate all stages of the 94 patients included in the study. Second- 
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and third late radiation complications were also added to the data source 
form. However, the patient data source form designed by the researcher 
for this retrospective study was very useful as a research tool and it 
provided detailed and summarised information of the patients` 
radiotherapy treatment details and follow-up notes.  At no stage was it  
necessary to refer to patient files to retrieve extra data for analysis. This 
research tool made the calculations of the BED values done at the 
Department of Biostatistics  quick and efficient. 
 
 
From January 1998 to December 2003, 696 patients diagnosed with 
uterine cervical cancer received radiotherapy treatment at the Department 
of Oncotherapy, Bloemfontein. Of these, only 94 patients met the patient 
selection criteria of this retrospective study. One-hundred and ninety-six 
patients had a follow-up period of less than two years, 348 patients had 
their follow-up examinations at clinics in other provinces and 58 patients 
did not have complete dosimetric data. The outcome of the study might 
have been different if 80% of the 696 patients could have been included 
into this study. 
 
 
5.7 Conclusion 
 
This retrospective study suggests that 50 Gy EBRT to the whole pelvis 
combined with HDR-ICBT with a median total dose of 18 Gy to point A, 
administered in 4-6 fractions, is an effective and safe fractionation 
schedule in the treatment of FIGO stages I-III uterine cervical cancer 
patients, if undertaken in a mean treatment period of 40.69 days. 
 
The cumulative median BED10 of 87.27 Gy10 to the tumour indicated 
acceptable local tumour control (88.3%). These BED10 values did not differ 
significantly (p=0.68), and so BED10 values could not be correlated with 
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local control. The cumulative median BED3 of 106 Gy3 to the rectum could 
also not be correlated to late radiation complications (p=0.17). The 
incidence of late radiation complications of the 94 patients treated was 
only 15.96%. Although this schedule appears to be both safe and 
effective, it is only a preliminary step to establishing windows of 
opportunity for BED10 to tumours and BED3 to rectal tissues.  
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6. SUMMARY 
 
 
A retrospective study was undertaken to determine if the fractionation schedule, 
which entails EBRT and HDR-ICBT, delivered acceptable biologically effective 
doses in treating FIGO stages I-III cervical cancer patients. The purpose of the 
calculated BED values was to see whether the cumulative biologically effective 
dose could be used as a predictor of local control and of rectal toxicity in the 
treatment of patients with cervical cancer. This study endeavoured to provide 
adequate fractionation details and calculated and correlated biologically effective 
dose to the tumour (Gy10) and late responding tissues e.g. the rectum (Gy3). The 
incidence of late radiation complications was analysed according to the 
RTOG/EORTC scoring criteria. 
 
The study was conducted on 94 patients (mean age of 55 years), from January 
1998 to December 2003, with FIGO stages I-III cervical cancer treated with a 
combination of EBRT and HDR-ICBT. A data source form was designed to 
retrieve information from the patients` radiotherapy treatment files and follow-up 
notes for analysis. The standard prescribed dose for EBRT was 2 Gy/fraction for 
25 fractions with a total dose of 50 Gy administered to the whole pelvis in a six 
week period. The HDR-ICBT treatment was delivered with an Ir192 Nucletron 
Microselectron and ring applicator. HDR-ICBT was interdigitated into the 
treatment only after two weeks of EBRT to allow for tumour shrinkage. The 
standard prescribed dose for HDR-ICBT was 2 Gy/fraction with the dose to point 
A normalised to the highest rectum dose point with a minimum total dose of 15 
Gy to point A. A median total dose of 18 Gy to point A was achieved in 4-6 
fractions. The mean overall treatment time was 41 days. 
 
The mean follow-up time was 40 months (3.3 years) and the overall survival of all 
94 patients FIGO stages I-III was 100%. Tumour control for all stages was 
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88.3% and the incidence of late radiation complications was 15.96%. Five 
patients had late rectal complications (Grade I-III) and ten patients had late 
bladder late complications (Grade I-III). One patient had grade IV (proctitis and 
cystitis). The median cumulative biologically effective dose was calculated to the 
tumour Gy10 and the rectum Gy3 by using the Linear quadratic model. The 94 
patients had a median cumulative BED10 of 87.27 Gy10 and a median cumulative 
BED3 of 106.26 Gy3. The median cumulative BED10 value for the tumour of 
87.27. Gy10 was 10-15% below those values reported in the literature, but 
delivered good tumour control. Longer follow-up results will, however, be 
required to determine if these lower Gy10 values comprise pelvic control rates. 
 
The median cumulative BED3 value for the rectum of 106.26 Gy3 was within the 
range of BED3 values (100-120 Gy3) reported in the literature. The eleven 
patients who presented with tumour recurrence had a median BED10 of 86.02 
Gy10 and those with late radiation complications had a median BED3 of 106.62 
Gy3. These BED10 and BED3 values could, however, not be correlated to tumour 
control (p=0.68) and late radiation complications (0.17) respectively. 
 
This retrospective study has indicated that the fractionation schedule of EBRT 
and HDR-ICBT as a radical treatment modality for FIGO stages I-III cervical 
cancer patients, with curative intent, had delivered acceptable pelvic control rates 
and a low incidence of late radiation complications at the Department of 
Oncotherapy, Universitas Annex, Bloemfontein. 
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7. OPSOMMING 
 
 
`n Retrospektiewe studie is onderneem om te bepaal of die fraksionasie skedule 
van eksterne bundel bestraling en intrakavitêre bragiterapie aanvaarbare 
biologiese effektiewe dosisse (BED) lewer in pasiënte wat gediagnoseer is met 
FIGO stadiums I-III servikale kanker. Die doel van die berekende BED waardes 
was om te sien of dit gebruik kan word as `n voorspelling vir lokale tumor beheer 
en laat rektale bestralings komplikasies. Die studie poog om voldoende 
fraksionasie besonderhede en berekende BED waardes aan die tumor en die 
laat responderende weefsel (bv. rektum) te verskaf. Die insidensie van laat 
rektale bestralings komplikasies is geanaliseer deur gebruik te maak van die 
RTOG/EORTC gradiëring sisteem. 
 
Dié studie fokus op die radioterapie behandeling van 94 pasiënte in die tydperk 
van Januarie 1998 tot Desember 2003. `n Inligtingsvorm is deur die navorser 
ontwerp om die relevante inligting van die pasiënte se bestralingslêers en 
opvolgnotas te versamel vir analise. 
 
Die voorgeskrewe protokol vir die eksterne bestraling sluit in 25 fraksies van 2 
Gy elk tot `n totale dosis van 50 Gy wat oor `n tydperk van ses weke toegedien 
word. Die bragiterapie behandeling word toegedien deur gebruik te maak van `n 
Ir192 Nucletron Mikroselektron na-ladings apparaat en ring applikators. Die 
voorgeskrewe dosis vir bragiterapie behels 2 Gy/fraksie wat voorgeskryf word 
aan die hoogste rektale dosis punt, met `n minimum dosis van 15 Gy aan punt A. 
Met bragiterapie is `n gemiddelde totale dosis van 18 Gy by punt A verkry in 4-6 
fraksies. Die gemiddelde behandelings tydperk was 41 dae. 
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Die gemiddelde opvolgtyd van die 94 pasiënte was 40 maaande (3.3 jaar). Die 
lokale tumor beheer vir al die pasiënte was 88.3%, terwyl die insidensie van laat 
bestralings komplikasies 15.96% was. Vyf van die 94 pasiënte het laat 
bestralings komplikasies (Graad I-III) ontwikkel an tien pasiënte het laat 
bestralings komplikasies (Graad I-III) van die blaas ontwikkel. Een pasiënt het 
met beide graad IV blaas en rektum komplikasies gepresenteer (proktitis & 
sistitis). 
 
Die Linêer kwadratiese model is gebruik om die BED van die tumor en die 
rektum te bereken. Die median totale BED10 van die 94 pasiënte was 87.27 Gy10 
en die mediane totale BED3 was 106.26 Gy3. Alhoewel die BED10 waarde van die 
tumor 10-15% minder was as dié van sommige gepubliseerde studies, is 
voldoende lokale tumor beheer verkry. Dit is egter nodig om na `n langer opvolg 
periode te kyk (5-10 jaar) om te bepaal of die laer BED10 waardes voldoende 
lokale tumor beheer gelewer het. 
 
Die mediane totale BED3 waarde aan die rektum van 106.26 Gy3, soos bepaal in 
die studie, vergelyk goed met die BED3 waardes (100-120 Gy3) wat in die 
literatuur gepubliseer is. Die 11 pasiënte wat met tumor herhaling gepresenteer 
het, het `n median BED10 waarde van 86.02 Gy10 gehad, terwyl die 15 pasiënte 
wat met laat bestralings komplikasies gepresenteer het, het `n mediane BED3 
waarde van 106.62 Gy3 gehad. Die BED10 en BED3 waardes het ongelukking nie 
gekorreleer met respektiewelik lokale tumor beheer (p=0.68) en laat bestralings 
komplikasies (p=0.17) nie. 
 
Hierdie retrospektiewe studie demonstreer dus dat die fraksionasie skedule wat 
vanaf April 1994 by die Onkoterapie Departement, Universitas Annex, 
Bloemfontein geïmplementeer is, aanvaarbare resultate lewer met betrekking tot 
lokale tumor beheer en die insidensie van laat bestralings komplikasies. 
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